Paramyotonia Congenita
Paramyotonia congenita is a rare autosomal dominant skeletal muscle sodium channelopathy characterized by cold-induced myotonia and paradoxical worsening of muscle stiffness with repeated activity, often followed by episodic weakness.
Paramyotonia Congenita (PMC)
Paramyotonia congenita (PMC) — let's break this name down from its roots:
- "Para" = paradoxical (Greek: beyond/contrary to)
- "Myo" = muscle (Greek: mys)
- "Tonia" = tone/tension
- "Congenita" = present from birth (Latin: congenitus)
The name literally tells you the condition: a paradoxical myotonia present from birth. It is "paradoxical" because the myotonia behaves opposite to classical myotonia — in typical myotonia (e.g. myotonia congenita), repeated muscle contraction improves the stiffness (the "warm-up phenomenon"). In paramyotonia congenita, repeated contraction worsens the stiffness. This is the "paradoxical" or "warm-down" phenomenon — the hallmark feature that distinguishes PMC from other myotonic disorders.
Paramyotonia congenita: AD inheritance, due to voltage-gated Na+ channel mutation (17q23). S/S: infantile onset, attacks of myotonia which ↑ in cold and hyperK, ↓ by hypoK, a/w flaccid weakness. [1]
Formal definition: Paramyotonia congenita is a rare, autosomal dominant skeletal muscle sodium channelopathy (SCN4A gene, chromosome 17q23) characterised by cold-induced and exercise-induced myotonia with a paradoxical worsening of stiffness on repeated activity, and episodic attacks of flaccid weakness. It belongs to the family of non-dystrophic myotonias and skeletal muscle ion channelopathies.
Key Conceptual Distinction
Myotonia = delayed relaxation after voluntary contraction (the muscle "locks up" — think of shaking someone's hand and being unable to let go).
Paramyotonia = myotonia that worsens with continued use (paradoxical) and is cold-provoked, unlike classical myotonia congenita where repetitive use improves stiffness (warm-up).
| Feature | Detail |
|---|---|
| Prevalence | Extremely rare; estimated ~1:100,000 to 1:250,000 worldwide [2] |
| Inheritance | Autosomal dominant with high penetrance |
| Sex distribution | M = F (equal, no sex predilection — unlike thyrotoxic periodic paralysis which is male-predominant) |
| Age of onset | Infantile onset [1] — symptoms typically recognised in infancy or early childhood; present from birth but may be noticed when the child is first exposed to cold |
| Ethnic distribution | Originally described in European (especially German) families (Eulenburg, 1886); reported worldwide but most published kindreds are of European descent. Uncommon in Hong Kong but must be differentiated from the far more common thyrotoxic periodic paralysis (TPP) and primary hypokalemic periodic paralysis in Asian populations |
| Genetic founder effects | Certain SCN4A mutations (e.g. T1313M, R1448C/H) are recurrent across unrelated families due to CpG dinucleotide hotspots |
Hong Kong Context
In Hong Kong clinical practice, PMC is a rare diagnosis. The differential diagnosis of episodic weakness and myotonia in a young Chinese patient must prioritise:
- Thyrotoxic periodic paralysis (TPP) — far more common in Asian males (up to 2% of hyperthyroid Asian patients) [3][4]
- Primary hypokalemic periodic paralysis — sporadic or familial
- Myotonia congenita — chloride channelopathy, more common than PMC globally
However, PMC should be considered when:
- Symptoms are clearly cold-provoked
- There is a paradoxical worsening with repeated contraction
- Family history of similar episodes (autosomal dominant)
- The patient is euthyroid with normal or elevated potassium during attacks
Since PMC is a monogenic autosomal dominant condition, the primary "risk factor" is having an affected parent (50% transmission risk per offspring). There are no modifiable risk factors for developing the disease itself. However, there are important attack precipitants/triggers:
| Trigger | Mechanism |
|---|---|
| Cold exposure | The most important trigger. Cold temperatures slow the inactivation kinetics of the mutant Na+ channel → persistent Na+ current → sustained depolarisation → myotonia progressing to weakness |
| Exercise / repeated contraction | Unlike myotonia congenita, exercise worsens (paradoxical) the stiffness. Activity in the cold is especially provocative |
| Hyperkalaemia | Attacks of myotonia ↑ in hyperK [1]. Elevated extracellular K+ further depolarises the membrane → more Na+ channels are in a partially depolarised state → exacerbates the gain-of-function defect |
| Potassium-rich foods | Dietary K+ load may precipitate attacks in susceptible individuals |
| Fasting | Can mildly raise serum K+ and trigger weakness |
| Rest after exercise | Similar to hyperkalemic periodic paralysis |
High Yield — Trigger Profile Comparison
| Feature | Paramyotonia Congenita | HypoK Periodic Paralysis | HyperK Periodic Paralysis | Thyrotoxic PP |
|---|---|---|---|---|
| Cold | +++ (cardinal) | ± | + | − |
| Carbohydrate load | − | +++ | − | +++ |
| Exercise | Worsens (paradoxical) | Post-exercise rest | Post-exercise rest | Post-exercise rest |
| K+ ingestion | + (worsens) | − | +++ | − |
| Thyrotoxicosis | − | − | − | Essential |
Anatomy and Physiology: The Voltage-Gated Sodium Channel (Nav1.4)
To understand PMC, you must understand the normal skeletal muscle sodium channel and the resting membrane potential.
-
Resting state: Skeletal muscle fibres maintain a resting membrane potential of approximately −85 to −90 mV, maintained by:
- Na+/K+ ATPase (3 Na+ out, 2 K+ in)
- K+ leak channels (high K+ permeability at rest)
- Cl⁻ channels (stabilise membrane potential — relevant for myotonia congenita)
-
Activation: When a motor neuron fires → acetylcholine at the NMJ → endplate potential → the membrane depolarises to threshold (~−55 mV) → voltage-gated Na+ channels (Nav1.4) open → massive Na+ influx → rapid depolarisation to ~+30 mV
-
Inactivation: Within 1-2 ms, the Nav1.4 channel inactivates — the inactivation gate (the "h-gate" or intracellular loop between domains III and IV) swings shut, stopping Na+ influx even while the channel is still in an "open" conformation. This is fast inactivation.
-
Recovery: The channel transitions from the inactivated state back to the resting (closed but activatable) state as the membrane repolarises. This recovery from inactivation allows the next action potential.
-
Repolarisation: K+ efflux through voltage-gated K+ channels restores the negative resting potential. Cl⁻ channels also help stabilise the membrane.
- Gene: SCN4A, located on chromosome 17q23 [1]
- Protein: Nav1.4, the α-subunit of the voltage-gated sodium channel expressed exclusively in skeletal muscle
- Structure: A single large polypeptide with 4 homologous domains (I–IV), each containing 6 transmembrane segments (S1–S6)
- S4 segments = voltage sensors (contain positively charged arginine/lysine residues that move outward upon depolarisation → channel opening)
- S5–S6 loop = forms the ion-selective pore
- III–IV intracellular loop = the inactivation gate (critical for fast inactivation)
Mutations in ion channels → leaky channels → failure to maintain stable resting action potential. Minor leakage (10-15mV) → myotonia. Major leakage (20-30mV) → periodic paralysis. Paroxysmal in nature: depends on neural activation of muscles. [1]
This is the unifying concept for all skeletal muscle channelopathies:
Aetiology
PMC is caused by gain-of-function mutations in SCN4A (the gene encoding the Nav1.4 skeletal muscle sodium channel α-subunit).
- Inheritance: Autosomal dominant [1]
- Penetrance: High (most carriers are symptomatic, though severity varies)
- Locus: Chromosome 17q23.1-q25.3
Common Mutations
| Mutation | Location | Phenotype | Notes |
|---|---|---|---|
| T1313M | Domain III-IV linker (inactivation gate) | Classic PMC | Most common; directly disrupts fast inactivation gate |
| R1448C | S4 segment of Domain IV (voltage sensor) | PMC ± periodic paralysis | Alters voltage sensing → impaired inactivation |
| R1448H | Same as above | PMC | |
| R1448P | Same as above | Severe PMC | |
| L1433R | S3 Domain IV | PMC with weakness | |
| I1393T | S3 Domain IV | PMC |
Most PMC mutations cluster in the voltage sensor (S4) of Domain IV or the III-IV intracellular linker (inactivation gate). This makes mechanistic sense — both regions are critical for fast inactivation of the sodium channel.
SCN4A mutations cause a spectrum of diseases depending on which part of the channel is affected and the degree of inactivation impairment:
| Disorder | Channel | Inheritance | Key Feature |
|---|---|---|---|
| Paramyotonia congenita | Na+ channel (SCN4A) | AD | Cold-induced paradoxical myotonia + weakness |
| Hyperkalemic periodic paralysis | Na+ channel (SCN4A) | AD | Episodic weakness triggered by K+, fasting, rest after exercise |
| Sodium channel myotonia (SCM) | Na+ channel (SCN4A) | AD | Pure myotonia without weakness; cold-insensitive or mildly cold-sensitive |
| Myotonia congenita | Cl⁻ channel (CLCN1) | AD (Thomsen) / AR (Becker) | Warm-up phenomenon; NOT paradoxical |
| Hypokalemic periodic paralysis | Ca²+ channel (CACNA1S) or Na+ (SCN4A) | AD | Triggered by CHO load, rest after exercise |
[1] Important examples: Cl⁻ channel → myotonia congenita; Na+ channel → paramyotonia congenita, hyperkalemic (K+-sensitive) periodic paralysis; Ca²+ channel → hypokalemic periodic paralysis, malignant hyperthermia.
Overlap Between PMC and HyperK PP
PMC and hyperkalemic periodic paralysis (HyperKPP) are allelic disorders — both caused by SCN4A mutations. There is significant clinical overlap. Some patients have features of both (myotonia + periodic paralysis). Historically they were considered separate entities, but modern molecular genetics shows they are part of a continuous spectrum of SCN4A channelopathies. The distinguishing clinical feature is: PMC = cold-induced paradoxical myotonia is the dominant symptom; HyperKPP = episodic weakness is the dominant symptom.
Pathophysiology
Let's walk through the pathophysiology step by step:
Step 1 — The Mutation Creates a "Leaky" Channel
PMC mutations (e.g. T1313M, R1448C) impair the fast inactivation process of Nav1.4. Normally, after the channel opens, the inactivation gate (III-IV linker) closes within 1-2 ms to terminate Na+ influx. In PMC, this gate is sluggish or incomplete → the channel re-opens (or fails to fully close) → persistent inward Na+ current.
Step 2 — Persistent Na+ Current Causes Membrane Depolarisation
The persistent Na+ influx shifts the resting membrane potential from −85 mV towards a more positive value. The degree of depolarisation determines the clinical phenotype:
-
Mild depolarisation (10-15 mV shift) → The membrane hovers near threshold → Repetitive, self-sustaining action potentials fire → MYOTONIA (the muscle contracts and cannot relax)
-
Severe depolarisation (20-30 mV shift) → So many Na+ channels are driven into the inactivated state that they cannot be recruited for normal action potentials → DEPOLARISATION BLOCK → the muscle becomes electrically inexcitable → FLACCID WEAKNESS (periodic paralysis)
Step 3 — Why Cold Worsens the Condition
Cold temperature has specific effects on the mutant Nav1.4 channel:
- Slows the kinetics of fast inactivation further — the already-impaired inactivation gate becomes even more sluggish at lower temperatures
- Slows recovery from inactivation — channels take longer to reset
- The overall effect: at cold temperatures, more channels remain in the persistent open/re-opening state → greater persistent Na+ current → more depolarisation → worsening myotonia → if severe enough, progresses to depolarisation block (weakness)
This explains the classic clinical sequence: Cold → myotonia → if cold exposure continues → weakness.
Step 4 — Why Repeated Contraction Worsens Myotonia (Paradoxical)
In normal muscle or in myotonia congenita (Cl⁻ channelopathy), repeated contraction "warms up" the muscle because:
- Normal Cl⁻ channels help stabilise the membrane after each contraction
- Each contraction cycle allows Na+ channels to recover and re-distribute normally
In PMC, each contraction:
- Opens more mutant Na+ channels
- Each opening produces a persistent Na+ current (because inactivation is defective)
- The cumulative persistent current worsens depolarisation with each successive contraction
- → More myotonia, not less = the paradox
Step 5 — Why Hyperkalaemia Worsens the Condition
Elevated extracellular K+ → reduced K+ gradient across the membrane → membrane depolarisation (Nernst equation). In a normal person, mild hyperkalaemia is tolerable. In PMC, the already-depolarised membrane is pushed further towards the depolarisation block threshold → worsening myotonia or precipitating weakness.
Conversely, attacks ↓ by hypoK [1] — low extracellular K+ hyperpolarises the membrane, moving it further from threshold and partially compensating for the persistent Na+ current.
Why PMC is a Gain-of-Function, Not Loss-of-Function
PMC mutations are gain-of-function: the Na+ channel does more than it should (stays open longer, conducts more Na+). This is different from loss-of-function channelopathies (e.g. some cardiac Na+ channelopathies causing Brugada syndrome, where the channel conducts less). The excess Na+ current is what drives the hyperexcitability (myotonia) and, paradoxically when extreme, the inexcitability (paralysis via depolarisation block).
Classification
PMC fits within a broader classification of muscle diseases:
Ion Channelopathies: Mutations in ion channels → leaky channels → failure to maintain stable resting action potential [1]
| Category | Channel | Gene | Disorder |
|---|---|---|---|
| Non-dystrophic myotonias | Cl⁻ | CLCN1 | Myotonia congenita (Thomsen/Becker) |
| Na+ | SCN4A | Paramyotonia congenita | |
| Na+ | SCN4A | Sodium channel myotonia | |
| Periodic paralyses | Na+ | SCN4A | Hyperkalemic periodic paralysis |
| Ca²+ / Na+ | CACNA1S / SCN4A | Hypokalemic periodic paralysis | |
| Other | Ca²+ (RyR1) | RYR1 | Malignant hyperthermia |
Myotonia: delayed muscle relaxation after contraction. Causes: myotonic dystrophy, myotonia congenita, paramyotonia congenita, proximal myotonic myopathy [1]
| Disorder | Dystrophic? | Channel/Gene | Warm-up? | Cold-sensitive? | Weakness? |
|---|---|---|---|---|---|
| Myotonic dystrophy type 1 | Yes (CTG repeat, DMPK) | Downstream channel dysfunction | Variable | Mild | Progressive distal |
| Myotonic dystrophy type 2 | Yes (CCTG repeat, ZNF9) | Downstream channel dysfunction | Variable | Mild | Progressive proximal |
| Myotonia congenita | No | Cl⁻ (CLCN1) | Yes (warm-up) | ↑ in cold, ↓ by warmth/exercise | Minimal |
| Paramyotonia congenita | No | Na+ (SCN4A) | No (paradoxical / warm-down) | +++ | Episodic flaccid weakness |
| Sodium channel myotonia | No | Na+ (SCN4A) | Variable | Variable | Absent or minimal |
This is the single most important clinical distinction between PMC and myotonia congenita:
| Myotonia Congenita | Paramyotonia Congenita | |
|---|---|---|
| With repeated use | Stiffness improves ("warm-up") | Stiffness worsens ("warm-down" / paradoxical) |
| Mechanism | Cl⁻ channel dysfunction → initial hyperexcitability, but with repeated use the membrane gradually stabilises | Na+ channel dysfunction → each contraction opens more mutant channels → cumulative persistent Na+ current → worsening depolarisation |
Exam Pearl — The 'Paradox' in Paramyotonia
If an exam question describes myotonia that worsens with repeated activity and is provoked by cold, the answer is paramyotonia congenita. If myotonia improves with repeated activity (warm-up phenomenon), think myotonia congenita.
Clinical Features
A. Symptoms
- The cardinal symptom of PMC
- Patients describe muscle "locking up" or "stiffness" when exposed to cold — e.g., going outside in winter, holding a cold drink, washing hands in cold water, swimming in cool water
- Distribution: Predominantly affects the face (especially orbicularis oculi — difficulty opening eyes after forceful closure), hands/forearms, and neck (tongue may also be affected → dysarthria)
- Why face and hands? These are the most exposed to environmental cold; additionally, facial and hand muscles have high density of Nav1.4 channels
- Paradoxical worsening: Unlike classical myotonia, the stiffness gets worse with continued or repeated activity in the cold. A patient who keeps trying to open and close their fist will find the hand becomes progressively stiffer
- Pathophysiological basis: Each contraction opens more mutant Na+ channels → cumulative persistent Na+ current → progressive membrane depolarisation → worsening myotonia
- After prolonged or severe cold exposure, the myotonia may progress to flaccid weakness lasting minutes to hours (occasionally up to a day)
- Distribution: Generalised but typically proximal > distal, lower limbs > upper limbs (similar to other periodic paralyses)
- Usually spares respiratory and bulbar muscles [1]
- Pathophysiological basis: Prolonged depolarisation from persistent Na+ current eventually pushes so many Na+ channels into the inactivated state → depolarisation block → electrical inexcitability of the sarcolemma → flaccid paralysis
- Triggers: Cold exposure (primary), rest after exercise, hyperkalaemia, potassium-rich foods
- Recovery is spontaneous upon rewarming and rest, typically within hours
- Patients may complain of difficulty:
- Releasing grip (e.g., unable to let go of a doorknob after gripping in the cold — the "handshake sign" is classic for myotonia in general)
- Opening eyes after forceful closure (orbicularis oculi myotonia)
- Speaking/swallowing difficulty in severe cold (tongue/pharyngeal myotonia → dysarthria)
- Walking on cold days (leg stiffness)
- Pathophysiological basis: All due to delayed relaxation of skeletal muscles from persistent Na+ channel activity
- Some patients report muscle discomfort or aching during myotonic episodes, though classically myotonia is described as painless
-
Myotonia: painless [1]
- However, in clinical practice, many patients with PMC do report a degree of discomfort, particularly during cold exposure. This may be related to sustained muscle contraction and relative ischaemia
-
- Infantile onset [1] — though many patients recall symptoms only from early childhood when they first experienced cold weather
- Symptoms are lifelong and non-progressive in terms of severity between attacks (unlike myotonic dystrophy, which is progressive)
- However, some patients develop mild fixed proximal weakness later in life (4th-6th decade), possibly due to cumulative myofibre damage from repeated depolarisation episodes
- Patients learn to avoid cold — may refuse outdoor activities in winter, always wear gloves
- Some patients note worsening after potassium-rich meals (bananas, oranges, potatoes)
- Family members often have identical symptoms (autosomal dominant)
B. Signs
Clinical tests for myotonia:
-
Grip myotonia: Ask the patient to make a tight fist and then rapidly open the hand. In PMC, there is delayed relaxation — the fingers slowly uncurl. Repeating this test should make it worse (paradoxical), unlike myotonia congenita where it improves
- Can be provoked by asking the patient to grip a cold object or immerse hands in cold water
-
Percussion myotonia: Tap the thenar eminence (or any accessible muscle belly) with a tendon hammer. A sustained dimpling or contraction of the muscle is seen, lasting several seconds, before it slowly relaxes
- Pathophysiological basis: Mechanical stimulation activates the mutant Nav1.4 channels → persistent depolarisation → sustained contraction at the site of percussion
-
Lid-lag myotonia (eyelid myotonia): Ask the patient to look up, then rapidly look down. The upper eyelids lag behind the downward gaze movement due to myotonia of the levator palpebrae superioris (Note: this is different from the lid lag of thyrotoxicosis, which is due to sympathetic overactivity of Müller's muscle)
-
Tongue myotonia: Ask the patient to protrude and retract the tongue rapidly. Myotonia causes the tongue to dimple or hesitate
Clinical tests for myotonia: grip myotonia and percussion myotonia [1] (see referenced diagram in Ryan Ho Neurology notes)
- Immersing the patient's hand or forearm in cold water (10-15°C) for 5-10 minutes is the classic provocation test
- After cold immersion:
- Grip strength markedly decreases
- Myotonia worsens dramatically
- In severe cases, the hand becomes weak (flaccid)
- Eyelid closure followed by attempted opening may show prolonged myotonia
- Between attacks: Muscle bulk is usually normal or even mildly hypertrophied (chronic low-level myotonia acts as a constant "workout")
- In contrast to myotonic dystrophy, where there is progressive wasting
- Some patients develop mild fixed proximal weakness in later decades
- During myotonic phase: Reflexes may be difficult to elicit due to the stiffness (the muscle is "locked" and resists the stretch reflex)
- During weakness phase: Hypotonia with hypo/areflexia (similar to other periodic paralyses — the muscle is electrically inexcitable) [1]
- Between attacks: Reflexes are normal
- Entirely normal — PMC is a pure skeletal muscle disorder; sensory neurons are not affected (they express different Na+ channel isoforms, e.g. Nav1.7, Nav1.8)
- This helps distinguish PMC from neuropathic causes of weakness
- No systemic features — unlike myotonic dystrophy, which has cataracts, cardiac conduction defects, endocrinopathy, cognitive dysfunction, etc.
- PMC is an isolated skeletal muscle disorder
- Facial appearance is normal (no myopathic facies, no frontal balding, no ptosis — these are features of myotonic dystrophy)
PMC vs Myotonic Dystrophy — Key Clinical Distinctions
| Feature | PMC | Myotonic Dystrophy |
|---|---|---|
| Myotonia | Cold-induced, paradoxical (warm-down) | Present at rest, warm-up phenomenon |
| Weakness | Episodic, cold-provoked | Progressive, distal > proximal |
| Muscle wasting | Absent/mild | Prominent (distal, temporalis, SCM) |
| Systemic involvement | None | Cataracts, cardiac, endocrine, cognitive |
| Facial appearance | Normal | Myopathic facies, frontal balding, ptosis |
| Inheritance | AD (SCN4A) | AD (DMPK, CTG repeat) |
| Genetic anticipation | No | Yes (trinucleotide repeat expansion) |
| Onset | Infantile, non-progressive | 15-40y, progressive |
The classic clinical vignette for PMC in an exam:
A young patient (often with a positive family history) presents with episodes of muscle stiffness affecting the face and hands, triggered by cold weather. The stiffness worsens with repeated use (paradoxical myotonia). After prolonged cold exposure, the stiffness may give way to flaccid weakness lasting minutes to hours. Between attacks, the patient is completely normal. Examination reveals percussion and grip myotonia that worsens with cold provocation. Sensory examination is normal. There are no systemic features.
Important Comparisons (for Clinical Approach)
| Feature | PMC | HyperK PP |
|---|---|---|
| Dominant symptom | Myotonia | Weakness |
| Cold sensitivity | +++ (cardinal) | + (mild) |
| Paradoxical myotonia | Yes (pathognomonic) | No (may have inter-attack myotonia) |
| K+ during attacks | Normal or mildly elevated | Elevated |
| Attack duration | Minutes to hours | 10 min to hours |
| Age of onset | Infancy | Infancy/childhood |
| Overlap | Some patients have both features (PMC + periodic paralysis) | Some patients have myotonia between attacks |
These two conditions are on a spectrum of SCN4A gain-of-function disorders. Some patients cannot be cleanly classified into one or the other. Genetic testing is the definitive differentiator.
| Feature | PMC (Na+) | Myotonia Congenita (Cl⁻) |
|---|---|---|
| Channel | SCN4A (Na+) | CLCN1 (Cl⁻) |
| Warm-up | No (paradoxical/warm-down) | Yes |
| Cold sensitivity | +++ | + (mild) |
| Weakness | Episodic flaccid weakness | Minimal |
| Muscle hypertrophy | Mild | Can be prominent ("Herculean" appearance in Becker type) |
| Inheritance | AD | AD (Thomsen) or AR (Becker) |
Non-dystrophic myotonic syndromes: Myotonia congenita — generalized myotonia which ↑ in cold and ↓ by warmth/exercise, minimal weakness [1]
Ion Channelopathies — Pathophysiology: Mutations in ion channels → leaky channels → failure to maintain stable resting action potential. Minor leakage (10-15mV) → myotonia. Major leakage (20-30mV) → periodic paralysis. Paroxysmal in nature: depends on neural activation of muscles. [1]
This framework is the single most important concept for understanding all skeletal muscle channelopathies, including PMC. The degree of "leak" (persistent current) determines whether the patient gets stiffness (myotonia) or weakness (paralysis) — and in PMC, both can occur sequentially as cold exposure progresses.
High Yield Summary
- Paramyotonia congenita = autosomal dominant Na+ channelopathy (SCN4A, 17q23) → gain-of-function → impaired fast inactivation of Nav1.4
- Cardinal feature: Cold-induced paradoxical myotonia (worsens with repeated contraction — "warm-down") ± episodic flaccid weakness
- Pathophysiology: Persistent Na+ current → mild depolarisation = myotonia; severe depolarisation = depolarisation block = paralysis
- Triggers: Cold (primary), hyperkalaemia, exercise, rest after exercise
- Infantile onset, lifelong, non-progressive (unlike myotonic dystrophy)
- No systemic features (unlike myotonic dystrophy: cataracts, cardiac, endocrine, cognitive)
- Allelic with hyperkalemic periodic paralysis (both SCN4A) — spectrum of disease
- Key differential: Myotonia congenita (Cl⁻ channel, warm-up phenomenon), hyperK PP, thyrotoxic PP (Asian males, check TFT), hypoK PP
- Ion channelopathy framework: Minor leak → myotonia; Major leak → paralysis
- Treatment: Mexiletine (Na+ channel blocker) is first-line for myotonia; avoid cold; manage hyperkalaemia; genetic counselling
Active Recall — Paramyotonia Congenita
[1] Senior notes: Ryan Ho Neurology.pdf, p.193–194 (Ion Channelopathies, Non-dystrophic myotonic syndromes, Periodic paralysis) [2] Statland JM, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018; general prevalence estimates [3] Senior notes: Maksim Medicine Notes.pdf, p.95 (Thyrotoxic periodic paralysis) [4] Senior notes: Ryan Ho Endocrine.pdf, p.29 (Thyrotoxic Periodic Paralysis) [5] Lecture slides: GC 056. Generalized muscle weakness.pdf, p.24 (Muscular dystrophies and myotonic dystrophy classification) [6] Lecture slides: Neurology- Two cases of lower limb weakness.pdf, p.18–20 (Pathological and anatomical differentials for weakness)
Differential Diagnosis of Paramyotonia Congenita
When a patient presents with the clinical phenotype suggestive of paramyotonia congenita — namely, cold-induced myotonia that worsens with repeated use (paradoxical) ± episodic flaccid weakness — you need a structured approach to differential diagnosis. The differentials can be organised into two overlapping clinical presentations that PMC can mimic:
- Conditions presenting with myotonia (delayed muscle relaxation)
- Conditions presenting with episodic weakness / periodic paralysis
The key clinical reasoning task is to determine:
- Is the stiffness truly myotonia (electrical phenomenon) vs. stiffness from other causes (e.g. spasticity, rigidity, contracture, cramp)?
- If myotonia is confirmed, which myotonic disorder is it?
- If episodic weakness is the presenting complaint, what is the cause of the periodic paralysis?
1. Myotonic Disorders (Primary Differentials for the Myotonic Component)
These are the conditions that share the key feature of myotonia (delayed muscle relaxation after voluntary contraction). The clinical task is to distinguish among them.
Myotonia: delayed muscle relaxation after contraction. Causes: myotonic dystrophy, myotonia congenita, paramyotonia congenita, proximal myotonic myopathy. [1][2]
| Feature | Detail |
|---|---|
| Channel / Gene | Cl⁻ channel (CLCN1), chromosome 7q35 [1] |
| Inheritance | AD (Thomsen) / AR (Becker) [1] |
| Onset | Infancy/childhood onset [1] |
| Key feature | Generalised myotonia which ↑ in cold and ↓ by warmth/exercise [1] — this is the classic warm-up phenomenon |
| Weakness | Minimal weakness [1] — transient weakness at onset of movement (Becker type may have more), but NO episodic flaccid paralysis |
| Muscle bulk | Often hypertrophied ("Herculean" appearance, especially in Becker type) — chronic myotonic contraction acts as constant isometric exercise |
| Systemic features | None |
Why this is different from PMC:
- The warm-up phenomenon is the cardinal distinguishing feature. In myotonia congenita, if you ask the patient to grip and release repeatedly, the stiffness improves. In PMC, it worsens (paradoxical).
- Mechanistic explanation: In myotonia congenita, the Cl⁻ channel is dysfunctional → reduced Cl⁻ conductance → membrane instability after contraction. However, with repeated contractions, the membrane gradually stabilises through compensatory K+ currents and Na+ channel inactivation (which is normal in myotonia congenita). In PMC, Na+ channel inactivation is the defect itself, so repeated contractions simply accumulate more persistent Na+ current → worsening.
- Myotonia congenita does not typically progress to flaccid weakness. PMC can.
- Cold sensitivity exists in both but is much more dramatic in PMC.
Exam Pearl — The Key Question to Ask
"Does your stiffness get better or worse with repeated use?"
- Better → Myotonia congenita (warm-up)
- Worse → Paramyotonia congenita (paradoxical / warm-down)
| Feature | Detail |
|---|---|
| Gene | CTG expansion at DMPK (19q13.3), AD inheritance [1][2] |
| Incidence | 5/100k births [1] |
| Onset | Usually onset at 15-40y, slowly progressive [1] |
| Myotonia | Present, but often not the dominant complaint; warm-up phenomenon is variable |
| Weakness | Weakness + wasting in distal muscles, temporalis, sternomastoid, facial and jaw muscles [1][2] — this is progressive, unlike PMC |
| Systemic features | Multisystem involvement: cataracts, cardiomyopathy/conduction disorders, endocrinopathy (DM, testicular atrophy), smooth muscle disorders (gut motility, constipation, poor bladder emptying), cognitive dysfunction [1][2] |
| Facial appearance | Characteristic myotonic facies [1] — long, thin face, ptosis, temporal wasting, frontal balding |
| Genetic anticipation | Yes — successive generations have more CTG repeats → earlier onset, worse severity |
Why this is different from PMC:
- DM1 is a dystrophic myotonia — there is progressive muscle wasting and weakness, which is completely different from the episodic, non-progressive nature of PMC
- The multisystem involvement is the giveaway: cataracts, cardiac conduction defects, diabetes, cognitive dysfunction — none of these occur in PMC
- DM1 weakness is distal > proximal (opposite to the periodic paralysis pattern of PMC which is proximal > distal)
- DM1 has genetic anticipation (trinucleotide repeat expansion); PMC does not (point mutation)
- DM1 can cause congenital hypotonia (congenital myotonic dystrophy, inherited from an affected mother) — this may present as a floppy infant, which is a different clinical scenario from PMC's infantile myotonia
Neuromuscular disorders including Duchenne muscular dystrophy, Becker muscular dystrophy, and myotonic dystrophy can be associated with familial dilated cardiomyopathy [3]
| Feature | Detail |
|---|---|
| Gene | CCTG repeat expansion in ZNF9 (CNBP), chromosome 3q21, AD |
| Onset | Adulthood (typically > 30 y) |
| Key feature | Proximal weakness (unlike DM1 which is distal) + myotonia + myalgia |
| Systemic | Similar to DM1 but generally milder: cataracts, cardiac involvement, insulin resistance |
Why this is different from PMC:
- Progressive proximal weakness + systemic features → clearly dystrophic
- Myalgia is prominent (PMC myotonia is usually described as stiffness, not pain)
- No cold provocation as a trigger
| Feature | Detail |
|---|---|
| Gene | SCN4A (same gene as PMC and HyperK PP) |
| Inheritance | AD |
| Key feature | Pure myotonia without episodic weakness |
| Cold sensitivity | Variable — some forms are cold-sensitive (potassium-aggravated myotonia), others are not |
| Warm-up | Variable — may or may not warm up |
Why this is different from PMC:
- The key distinction is that SCM patients do not develop episodic flaccid weakness
- Cold sensitivity is less prominent or absent in many SCM subtypes
- The paradoxical phenomenon is typically absent or less dramatic
- This is essentially the "mildest" end of the SCN4A gain-of-function spectrum: enough persistent Na+ current for myotonia, but not enough to cause depolarisation block
SCM, PMC, and HyperK PP are allelic disorders — all SCN4A mutations. They represent a clinical spectrum: SCM (myotonia only) → PMC (cold-induced paradoxical myotonia + weakness) → HyperK PP (episodic weakness ± inter-attack myotonia). Some patients have overlapping features.
2. Periodic Paralyses (Primary Differentials for the Weakness Component)
When the episodic flaccid weakness is the presenting or dominant complaint, the differential broadens to the periodic paralysis family.
Periodic paralysis: characterised by episodic generalised flaccid weakness of varying severity, usually spares respiratory and bulbar muscles, lasts 10 min to several hours [1]
| Feature | Detail |
|---|---|
| Gene | SCN4A (same as PMC!) [1] |
| Inheritance | AD, rare (1/200k), M:F = 1:1 [1] |
| Onset | Infantile/childhood onset [1] |
| Triggers | Exercise, fasting, cold exposure, anaesthesia, ingestion of K+ salts [1] |
| K+ during attack | Mild hyperK [1] |
| Myotonia | Myotonia between attacks [1] — but typically warm-up, not paradoxical |
| Weakness pattern | Focal or generalised weakness with hypotonia [1] |
| Long-term | May develop proximal myopathy after attacks subside in 4th-6th decades [1] |
Why this overlaps with and differs from PMC:
- Both are SCN4A mutations → significant clinical overlap
- HyperK PP → weakness is the dominant feature; myotonia is present between attacks but is not cold-provoked in the dramatic, paradoxical way seen in PMC
- PMC → myotonia is the dominant feature; weakness follows cold-induced myotonia
- Some patients have features of both → "PMC with periodic paralysis" or "overlap syndrome"
- Genetic testing is often needed to differentiate definitively
| Feature | Detail |
|---|---|
| Gene | CACNA1S (Ca²+ channel, most common) or SCN4A [1] |
| Inheritance | AD (familial), F > M in familial form; sporadic form M > F [1] |
| Onset | Late teenage/childhood onset [1] |
| Triggers | Heavy exercise, CHO load, hyperinsulinaemia, β2-agonists (after a delay of several hours) [1] |
| K+ during attack | Hypokalemia [1] |
| Myotonia | Absent — this is the key distinguishing feature |
| Weakness pattern | Proximal > distal, LL > UL, hyporeflexia during attacks, normal between attacks [1] |
| Long-term | May develop progressive proximal myopathy > 50y [1] |
Why this is different from PMC:
- No myotonia — the presence of myotonia essentially rules out primary HypoK PP
- K+ is low during attacks (in PMC it is normal or mildly elevated)
- Triggered by carbohydrate load and rest after exercise, not cold
- Different channel: CACNA1S (Ca²+ channel) in most cases
This is the most important differential in the Hong Kong exam context for any episodic weakness presentation, because it is common in Asian males.
| Feature | Detail |
|---|---|
| Epidemiology | Up to 2% among Asian patients with hyperthyroidism; predominantly in male patients (25% M vs 0.8% F); >95% male [4][5] |
| Pathophysiology | Thyrotoxicosis → ↑Na+/K+/ATPase activity + ↑insulin release (esp after carbohydrate load) → intracellular shift of K+ [4] |
| Essential prerequisite | Always preceded by thyrotoxic S/S; thyrotoxic state essential for pathogenesis [4] |
| Classic vignette | A Chinese young male cannot stand up from chair after a heavy meal or exercise [5] |
| K+ during attack | Severe hypoK (mean 2.1, can be < 1.5) [4] |
| Myotonia | Absent |
| Triggers | Events a/w ↑adrenaline release (rest after exercise, stress, SABA) or ↑insulin release (carbohydrate load) [4] |
| Weakness pattern | Proximal > distal, LL > UL, seldom respiratory/bulbar muscles [4] |
| Reflexes | Preserved reflexes (c.f. GBS) [5] — though some sources say hypo/areflexia during attacks |
Why this is different from PMC:
- No myotonia — TPP is pure periodic paralysis
- Hypokalemia during attacks (PMC has normal/elevated K+)
- Thyrotoxic features are always present: weight loss, tremor, palpitations, heat intolerance, goitre, etc.
- Not cold-triggered — in fact, heat intolerance is a feature of thyrotoxicosis
- TPP is acquired (resolves when euthyroidism is restored); PMC is genetic (lifelong)
- TPP is a secondary form of hypoK PP; PMC is a primary channelopathy
D/dx of primary HypoK PP: TPP (check TFT) and weakness due to secondary hypoK (RFT, TTKG, normoK between attacks) [1]
High Yield — TPP vs PMC in Hong Kong Exams
In a Hong Kong exam, if a young Asian male presents with episodic weakness after a heavy meal, the examiner is almost certainly testing you on TPP — check TFT and serum K+. If the presentation is cold-induced stiffness progressing to weakness, with paradoxical myotonia and a family history, think PMC. The presence or absence of myotonia and thyrotoxic features is the clinical fork in the road.
| Feature | Detail |
|---|---|
| Gene | KCNJ2 (Kir2.1 inward rectifier K+ channel), chromosome 17q24.3 |
| Inheritance | AD |
| Triad | (1) Periodic paralysis, (2) cardiac arrhythmias (prolonged QT, bidirectional VT, prominent U waves), (3) dysmorphic features (micrognathia, hypertelorism, low-set ears, clinodactyly, short stature) |
| K+ during attack | Variable — can be hypo, normo, or hyperkalemic |
Why this is different from PMC:
- No myotonia
- Dysmorphic features present
- Cardiac arrhythmias are a defining feature (whereas cardiac involvement in PMC is absent or minimal)
- Much rarer
3. Non-Myotonic Conditions Mimicking Muscle Stiffness
These conditions may present with "stiffness" or difficulty relaxing muscles, but the mechanism is NOT myotonia (not an electrical phenomenon of the muscle membrane).
- Mechanism: Autoimmune (anti-CASPR2 or anti-LGI1 antibodies) or paraneoplastic → peripheral nerve hyperexcitability
- Features: Continuous muscle fibre activity, muscle stiffness, cramps, fasciculations, pseudomyotonia (appears similar but EMG shows neuromyotonic discharges originating from peripheral nerves, not the muscle membrane itself)
- Different from PMC: Acquired (not congenital), continuous (not paroxysmal), associated with autonomic dysfunction (hyperhidrosis), no cold provocation, EMG shows characteristic high-frequency decrementing bursts
- Mechanism: Autoimmune (anti-GAD65 antibodies) → loss of GABAergic inhibition in spinal cord → continuous muscle contraction
- Features: Progressive stiffness and rigidity of axial and proximal limb muscles, exaggerated startle response, superimposed painful spasms
- Different from PMC: Acquired in adulthood, continuous (not episodic), axial predominance, anti-GAD65 positive, no myotonia on EMG, no cold provocation
- Mechanism: Hypothyroidism → slowed muscle metabolism, accumulation of glycosaminoglycans in muscle, impaired Ca²+ handling → delayed muscle relaxation (pseudomyotonia)
- Features: Generalised muscle stiffness, proximal weakness, "mounding phenomenon" (percussion causes a local mound that relaxes slowly), CK may be elevated
- Different from PMC: Acquired, associated with other hypothyroid features (weight gain, cold intolerance, constipation, dry skin, bradycardia), TFT shows elevated TSH/low fT4, "pseudomyotonia" — EMG is electrically silent during the delayed relaxation (true myotonia shows electrical activity)
Endocrine causes of myopathy include hyper/hypothyroidism, Cushing's syndrome [6][7]
- Mechanism: Mutation in ATP2A1 (SERCA1 — sarcoplasmic reticulum Ca²+-ATPase) → impaired Ca²+ re-uptake into SR after contraction → delayed muscle relaxation
- Features: Exercise-induced muscle stiffness (not cold-induced), especially in legs; EMG is electrically silent during the stiffness (not true myotonia)
- Different from PMC: AR inheritance, exercise-triggered (not cold), EMG silent (pseudo-myotonia), no paradoxical phenomenon
- Mechanism: Mutation in CAV3 (caveolin-3) → abnormal muscle membrane mechanics
- Features: Percussion-induced muscle mounding + rolling contractions (visible wave of contraction across muscle), muscle stiffness
- Different from PMC: The "rippling" is mechanical and electrically silent; distinct genetic basis
4. Other Causes of Episodic Weakness (Not Myotonic)
These are conditions that may present with episodic or fluctuating weakness but are fundamentally different in mechanism.
- Mechanism: Autoimmune (anti-AChR or anti-MuSK antibodies) → impaired neuromuscular junction transmission
- Features: Fatigable weakness — gets worse with sustained or repeated use, improves with rest (opposite to PMC where stiffness worsens with use but then weakness appears). Typically affects extraocular muscles (ptosis, diplopia), bulbar muscles (dysarthria, dysphagia), and proximal limbs
- Different from PMC: Fatigable (not myotonic), no stiffness/delayed relaxation, extraocular and bulbar involvement is common (rare in PMC), no cold sensitivity, decremental response on repetitive nerve stimulation, positive anti-AChR antibodies
GC 056 Generalised muscle weakness lecture covers classification of NMJ disorders including myasthenia gravis [8]
- Mechanism: Post-infectious autoimmune demyelinating polyneuropathy → ascending flaccid paralysis
- Features: Acute/subacute ascending weakness, areflexia, may have sensory symptoms, bulbar and respiratory involvement possible, albuminocytological dissociation in CSF
- Different from PMC: Monophasic (not episodic), progressive over days-weeks, sensory involvement, no myotonia, recent preceding infection, CSF protein elevation
- Muscle weakness, paralysis (proximal muscle myopathy) can result from hypokalemia from any cause [9]:
- Renal losses: diuretics, renal tubular acidosis, Bartter/Gitelman syndrome, hyperaldosteronism
- GI losses: vomiting, diarrhoea, laxative abuse
- Transcellular shift: insulin, β2-agonists, alkalosis
- Different from PMC: No myotonia, K+ is low (and low total body K+, unlike TPP where total body K+ is normal), associated features depend on the underlying cause
| Condition | Channel/Gene | Inheritance | Myotonia | Paradoxical | Cold-Triggered | K+ During Attack | Weakness | Systemic Features |
|---|---|---|---|---|---|---|---|---|
| Paramyotonia Congenita | Na+ / SCN4A | AD | +++ | YES | +++ | Normal/↑ | Episodic flaccid | None |
| Myotonia Congenita | Cl⁻ / CLCN1 | AD/AR | +++ | No (warm-up) | + | Normal | Minimal | None |
| Sodium Channel Myotonia | Na+ / SCN4A | AD | +++ | Variable | Variable | Normal | None | None |
| HyperK Periodic Paralysis | Na+ / SCN4A | AD | + (between attacks) | No | + | ↑ | Episodic flaccid | None |
| HypoK Periodic Paralysis | Ca²+ / CACNA1S | AD | None | No | No | ↓ | Episodic flaccid | None |
| Thyrotoxic PP | Acquired | N/A | None | No | No | ↓↓ | Episodic flaccid | Thyrotoxicosis |
| Myotonic Dystrophy 1 | CTG / DMPK | AD | ++ | No (warm-up) | ± | Normal | Progressive distal | Cataracts, cardiac, endocrine, cognitive |
| Myotonic Dystrophy 2 | CCTG / ZNF9 | AD | + | No | ± | Normal | Progressive proximal | Similar to DM1 (milder) |
| Andersen-Tawil | K+ / KCNJ2 | AD | None | No | No | Variable | Episodic | Dysmorphism, cardiac arrhythmia |
| Neuromyotonia | Acquired (autoimmune) | N/A | Pseudo | No | No | Normal | Rare | Hyperhidrosis, autonomic |
| Myasthenia Gravis | Acquired (autoimmune) | N/A | None | No | No | Normal | Fatigable | Thymoma, other autoimmune |
| Hypothyroid myopathy | Acquired | N/A | Pseudo | No | No | Normal | Proximal | Hypothyroid features |
When faced with a patient presenting with myotonia and/or episodic weakness, systematically ask:
-
Is there true myotonia? (EMG confirmation if doubt)
- Yes → Myotonic disorder (PMC, myotonia congenita, DM1/2, SCM)
- No → Periodic paralysis, NMJ disorder, or pseudomyotonia
-
Does the myotonia warm up or warm down?
- Warm-up → Myotonia congenita
- Warm-down (paradoxical) → Paramyotonia congenita [1]
- Variable → SCM or DM1/2
-
Is cold the dominant trigger?
- Yes (+++) → PMC
- Mild → Myotonia congenita, HyperK PP
- No → DM1/2, HypoK PP, TPP
-
Is there episodic weakness?
- Yes → Check K+ during attack
- No → Pure myotonia (myotonia congenita, SCM)
-
What is the K+ during attack?
- Low → HypoK PP or TPP → check TFT
- High → HyperK PP or PMC with weakness
- Normal → Andersen-Tawil or secondary causes
-
Are there systemic features?
- Cataracts, cardiac, cognitive → DM1/2
- Thyrotoxic features → TPP
- Dysmorphism + cardiac arrhythmia → Andersen-Tawil
- None → PMC, myotonia congenita, SCM, HyperK PP
-
Family history?
- AD with high penetrance → PMC, HyperK PP, DM1, myotonia congenita (Thomsen)
- AR → Myotonia congenita (Becker type)
- Sporadic → TPP, secondary causes
Differential diagnosis of myopathy: Infective, Neoplastic/Paraneoplastic, Inflammatory, Congenital (Muscular dystrophy), Autoimmune (Dermatomyositis, necrotising autoimmune myositis), Trauma/toxin (crush injuries, glucocorticoids, colchicine, statins), Endocrine (Hypothyroidism, Cushing's, hypokalemia) [6]
Channelopathy differentials include myotonic dystrophy, periodic paralysis (thyrotoxic, hyperkalemic, hypokalemic) [10]
The following features should make you reconsider the diagnosis of PMC and think about alternative conditions:
| Red Flag | Suggests Instead |
|---|---|
| Progressive wasting | Myotonic dystrophy, muscular dystrophy |
| Cataracts or cardiac conduction defects | Myotonic dystrophy |
| Thyrotoxic symptoms | Thyrotoxic periodic paralysis |
| Sensory involvement | Neuropathy (GBS, CIDP, etc.) |
| Bulbar/respiratory involvement | GBS, MG, MND |
| Fatigable weakness | Myasthenia gravis |
| Severe hypokalemia ( < 2.0) during attack | HypoK PP or TPP |
| Onset in adulthood | DM1/2, TPP, inflammatory myopathy |
| No family history + adult onset | Acquired cause (TPP, statin myopathy, inflammatory myopathy) |
| Dysmorphic features | Andersen-Tawil syndrome |
High Yield — The 3 Key Differentiators for PMC on Exam
If the exam gives you a vignette of episodic muscle problems, ask yourself three things:
- Is there myotonia? (If no → not PMC)
- Is it cold-provoked and paradoxical? (If yes → PMC)
- Is the patient euthyroid with normal/high K+? (If thyrotoxic or hypoK → TPP/HypoK PP instead)
These three questions will get you the right answer in > 90% of exam scenarios.
High Yield Summary
- The differential for PMC is organised around two axes: myotonia (PMC vs myotonia congenita vs DM1/2 vs SCM) and episodic weakness (PMC vs HyperK PP vs HypoK PP vs TPP vs Andersen-Tawil)
- Paradoxical myotonia (warm-down, worsens with repeated use) is essentially pathognomonic for PMC — myotonia congenita has warm-up
- Cold provocation as the dominant trigger strongly favours PMC over all other periodic paralyses
- PMC and HyperK PP are allelic (both SCN4A) with significant overlap — distinguished by whether myotonia or weakness dominates
- TPP is the most important differential in Hong Kong — always check TFT in any Asian male with episodic weakness; TPP has no myotonia, has hypoK, and has thyrotoxic features
- Myotonic dystrophy is distinguished by progressive wasting + multisystem involvement (cataracts, cardiac, endocrine, cognitive)
- Pseudomyotonia (hypothyroidism, Brody disease, neuromyotonia) can mimic the stiffness but is electrically silent on EMG
- No sensory involvement, no bulbar involvement, and no systemic features in PMC — their presence should redirect to other diagnoses
Active Recall — Differential Diagnosis of Paramyotonia Congenita
References
[1] Senior notes: Ryan Ho Neurology.pdf, p.191–194 (Ion Channelopathies, Non-dystrophic myotonic syndromes, Periodic paralysis, Diseases of Muscles) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.145 (Myotonic Dystrophy, causes of myotonia) [3] Senior notes: Block A - Inherited Cardiac conditions.pdf, p.5 (Neuromuscular disorders associated with familial DCM) [4] Senior notes: Ryan Ho Endocrine.pdf, p.29 (Thyrotoxic Periodic Paralysis) [5] Senior notes: Maksim Medicine Notes.pdf, p.95 (Thyrotoxic periodic paralysis) [6] Lecture slides: Neurology- Two cases of lower limb weakness.pdf, p.38 (Differential Diagnosis of Myopathy) [7] Lecture slides: CFB_Neuro clinical skills demonstration_01.08.22_file to students.pdf, p.8 (Pathological differentials for weakness including endocrine causes) [8] Lecture slides: GC 056. Generalized muscle weakness.pdf, p.1 (Learning objectives including NMJ disorders and myopathy) [9] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf, p.27 (Hypokalemia complications including muscle weakness) [10] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.706 (Differential diagnosis of myopathies including channelopathies)
Diagnostic Criteria, Algorithm & Investigations for Paramyotonia Congenita
I. Diagnostic Criteria
Unlike conditions such as rheumatoid arthritis or SLE, paramyotonia congenita does not have a formal set of published classification criteria (e.g., ACR/EULAR criteria). This is because it is an ultra-rare monogenic disorder where the diagnosis rests on a combination of characteristic clinical features + electrophysiology + genetic confirmation. The diagnostic approach is therefore a clinical-genetic one rather than a criteria-based one.
However, the diagnosis can be made with high confidence when the following elements are present:
| # | Feature | Rationale |
|---|---|---|
| 1 | Cold-induced myotonia — muscle stiffness provoked or dramatically worsened by cold exposure, affecting face, hands, and/or neck | Cardinal clinical feature; reflects the temperature-dependent slowing of mutant Nav1.4 inactivation |
| 2 | Paradoxical myotonia — stiffness worsens with repeated contraction (warm-down), rather than improving (warm-up) | Pathognomonic for PMC; distinguishes from myotonia congenita (Cl⁻ channelopathy) |
| 3 | Episodic weakness — flaccid weakness following cold-provoked myotonia, lasting minutes to hours, sparing respiratory/bulbar muscles | Reflects progression from myotonia (mild depolarisation) to depolarisation block (severe depolarisation) |
| 4 | Autosomal dominant family history — affected parent or siblings with identical symptoms (high penetrance) | Consistent with AD inheritance of SCN4A mutations; de novo mutations are rare but possible |
| 5 | Infantile/childhood onset — symptoms from birth or early childhood, non-progressive between attacks | Distinguishes from acquired disorders and myotonic dystrophy (onset 15-40y, progressive) |
| 6 | Absence of systemic features — no cataracts, cardiac conduction defects, endocrinopathy, or cognitive dysfunction | Distinguishes from myotonic dystrophy, which is multisystem |
| Feature | Comment |
|---|---|
| Myotonic discharges on EMG (especially cold-provoked) | Electrical confirmation of myotonia; distinguishes from pseudomyotonia (electrically silent) |
| Normal or mildly elevated serum K+ during attacks | Distinguishes from hypoK PP and TPP; aligns with Na+ channelopathy spectrum |
| Normal serum CK between attacks (may be mildly elevated during/after attacks) | Unlike inflammatory myopathies where CK is markedly elevated |
| Normal TFT | Essential to rule out thyrotoxic periodic paralysis, especially in Asian populations |
| Pathogenic SCN4A variant on genetic testing | Gold standard / confirmatory — definitively establishes the diagnosis |
When is the Diagnosis 'Definite' vs 'Probable'?
- Definite PMC: Characteristic clinical phenotype (features 1-6 above) + pathogenic SCN4A variant identified on genetic testing
- Probable/Clinical PMC: Characteristic clinical phenotype + EMG evidence of myotonia (especially cold-provoked) + AD family history, without genetic confirmation (e.g., variant of uncertain significance, or testing not available)
- Possible PMC: Suggestive clinical features but incomplete phenotype or atypical presentation → requires further workup to exclude differentials
The diagnostic algorithm for PMC follows a logical sequence: clinical suspicion → exclusion of common mimics → electrophysiological confirmation → genetic confirmation. This mirrors the general principle in neuromuscular disease workup:
Investigations for muscle diseases: CK, lactate → EMG → Regional MRI → Muscle biopsy → Genetic testing [1][11]
For PMC specifically, the algorithm is more streamlined because it is a channelopathy (not a structural myopathy), so muscle biopsy is rarely needed.
III. Investigation Modalities — Detailed Breakdown
These are "investigations" you perform at the bedside before ordering any tests:
| Test | Method | Expected Finding in PMC | What It Tells You |
|---|---|---|---|
| Grip myotonia | Ask patient to make tight fist then rapidly open hand | Delayed finger extension; worsens with repeated attempts | Confirms myotonia + paradoxical (warm-down) nature |
| Percussion myotonia | Tap thenar eminence with reflex hammer | Sustained dimple/contraction lasting several seconds | Confirms electrical hyperexcitability of muscle membrane |
| Eyelid myotonia | Forceful eye closure → attempt to open | Delayed lid opening | Myotonia of orbicularis oculi |
| Cold provocation | Immerse forearm/hand in cold water (10-15°C) for 5-10 min, then re-test grip and percussion | Dramatic worsening of myotonia; possible development of flaccid weakness of the hand | The cardinal provocation test for PMC; the cold-dependence of symptoms is the disease-defining feature |
| Warm-up vs warm-down assessment | Repeated grip-release cycles (10-15 times) | Stiffness progressively worsens (paradoxical) | Distinguishes PMC (warm-down) from myotonia congenita (warm-up) |
Myotonia clinical tests: [grip myotonia and percussion myotonia] — features: painless, often temperature related (↑ when cold), warming-up/down phenomenon (↓ by repeated muscle contraction) [1][2]
| Investigation | Expected Finding in PMC | Interpretation / Why It's Done |
|---|---|---|
| Serum K+ | Normal (3.5-5.0 mmol/L) between attacks; normal or mildly elevated during attacks | PMC is a Na+ channelopathy → K+ disturbance is NOT the primary mechanism (unlike TPP where K+ is low due to transcellular shift, or HyperK PP where K+ is elevated). Checking K+ is essential to rule out hypokalemic and hyperkalemic periodic paralyses as the primary diagnosis. If K+ is dramatically low (< 2.5), think TPP or primary HypoK PP instead |
| TFT (TSH, fT4) | Normal (euthyroid) | Essential to rule out thyrotoxic periodic paralysis (TPP) — the most common cause of episodic paralysis in Asian populations [4][5]. If TSH is suppressed and fT4 is elevated → the diagnosis is TPP, not PMC. In PMC, the thyroid is normal. |
| Serum CK | Normal between attacks; may be mildly elevated during or shortly after an attack (due to transient muscle membrane instability and minor myofibre damage) | Markedly elevated CK (> 10× ULN) suggests inflammatory myopathy, rhabdomyolysis, or muscular dystrophy — not PMC. Mild CK elevation in PMC occurs because the persistent Na+ current and depolarisation block can cause minor reversible muscle injury during attacks |
| RFT (Cr, BUN) | Normal | Rule out renal causes of electrolyte disturbance; rule out rhabdomyolysis (if CK markedly elevated, check for myoglobinuria and acute kidney injury) |
| CBC | Normal | Baseline; rule out infection or haematological causes |
| LFT | Normal | Baseline; CK elevation is more specific than AST/ALT for muscle disease, but both AST and ALT can be elevated from muscle origin (not liver) |
| Glucose | Normal | Hyperinsulinaemia triggers attacks in HypoK PP and TPP (carbohydrate load); less relevant for PMC but still part of baseline metabolic workup |
High Yield — The 'Rule-Out' Bloods for Episodic Weakness
In any patient with episodic weakness, three blood tests are non-negotiable before pursuing a channelopathy diagnosis:
- Serum K+ (during attack if possible) — distinguishes hypoK vs hyperK vs normoK periodic paralysis
- TFT — rules out TPP (extremely common in Asian males)
- CK — rules out inflammatory myopathy, dystrophy, rhabdomyolysis
These correspond to the general approach for muscle disease investigations:
Investigations for muscle diseases: CK, lactate, EMG, regional MRI, muscle biopsy [1][11]
| Finding | Interpretation |
|---|---|
| Usually normal between attacks | PMC does not cause intrinsic cardiac conduction disease (unlike myotonic dystrophy) |
| During attacks: may show changes of mild hyperK if K+ is elevated — peaked T waves, widened QRS | The transient mild hyperK during PMC attacks can produce ECG changes; however, these are rarely as severe as in primary HyperK PP |
| Absence of hypoK ECG changes (no U waves, no ST depression, no QT prolongation) | Helps rule out hypoK PP and TPP, where ECG changes of hypoK include large U wave, loss of T wave, prolonged QT interval [9] |
| No long QT, no Brugada pattern | Rules out inherited cardiac channelopathies (LQTS, Brugada syndrome) — these involve cardiac-specific Na+ channels (SCN5A), not the skeletal muscle channel (SCN4A) |
Cardiac arrhythmia, particularly when K+ < 2.0 [9] — this severe hypoK with arrhythmia is characteristic of TPP/HypoK PP, not PMC.
Why ECG matters: Although PMC is a skeletal muscle Na+ channelopathy (SCN4A, not cardiac SCN5A), ECG is still important because:
- Electrolyte disturbances during attacks can cause arrhythmia
- Must exclude Andersen-Tawil syndrome (KCNJ2), which has periodic paralysis + cardiac arrhythmia (prolonged QT, prominent U waves, bidirectional VT)
- Must exclude myotonic dystrophy, which has cardiac conduction defects
Step 4: Electrophysiology (EMG and NCS)
This is the key confirmatory investigation before genetic testing.
Investigation approach for peripheral hypotonia: Nerve conduction study → CK level → EMG → Muscle biopsy → Genetic study [2]
EMG is the investigation that confirms the electrical nature of myotonia and distinguishes true myotonia from pseudomyotonia.
| Finding | Description | Significance |
|---|---|---|
| Myotonic discharges | Repetitive, waxing-and-waning high-frequency discharges on needle EMG, producing the characteristic "dive-bomber" sound | Confirms TRUE myotonia (electrical hyperexcitability of the muscle membrane). This is the electrical correlate of the clinical myotonia you see at the bedside. The "dive-bomber" sound is produced by the changing frequency and amplitude of the myotonic runs — like the whine of a WWII dive-bomber plane |
| Worsening with cooling | Myotonic discharges increase in frequency and duration when the muscle is cooled (e.g., by applying ice packs to the limb during EMG) | Myotonia ↑ in cold [1] — this temperature-dependent worsening on EMG is highly characteristic of PMC. In myotonia congenita, myotonic discharges may also increase with cold but to a lesser extent |
| CMAP amplitude decrement after cooling | Compound muscle action potential (CMAP) amplitude decreases after the limb is cooled for 20-30 minutes | This reflects the progression from myotonia to depolarisation block → as more Na+ channels enter the inactivated state at cold temperatures, fewer are available for normal action potential generation → the CMAP (which reflects the summed electrical activity of all muscle fibres under a motor unit) decreases. This is essentially the electrophysiological correlate of the clinical weakness |
| Fibrillation potentials | May be present, especially in muscles that have undergone repeated attacks | Indicates some degree of muscle membrane instability at rest; can also be seen in denervation and inflammatory myopathies. In PMC, fibrillation potentials reflect the persistent Na+ current causing spontaneous depolarisation of individual muscle fibres |
EMG protocol for suspected PMC (cooling protocol):
- Baseline EMG at room temperature — look for myotonic discharges
- Record CMAP amplitude at room temperature
- Cool the limb (ice packs, cold water immersion) for 20-30 minutes
- Repeat EMG — expect increased myotonic discharges and decreased CMAP amplitude
- Rewarm the limb — expect gradual normalisation
This cooling EMG protocol is highly sensitive and relatively specific for PMC. The combination of worsening myotonic runs + CMAP decrement on cooling is characteristic.
EMG: True Myotonia vs Pseudomyotonia
A common exam pitfall: Pseudomyotonia (e.g., in hypothyroidism or Brody disease) produces clinical stiffness that looks like myotonia, but on EMG the muscle is electrically silent during the delayed relaxation. True myotonia always shows myotonic discharges (repetitive electrical activity) on EMG. If the EMG is silent during the "stiffness," it is NOT myotonia and PMC is excluded.
| Finding | Significance |
|---|---|
| Usually normal | Confirms that the peripheral nerves are intact — this is a muscle membrane (channelopathy) problem, not a neuropathy. Normal NCS helps rule out neuropathic causes of weakness (GBS, CIDP, hereditary neuropathies) |
| CMAP amplitude may be reduced after cooling | As above — reflects depolarisation block of muscle fibres, not nerve conduction failure |
| No conduction block or temporal dispersion | These are features of demyelinating neuropathy (GBS, CIDP), not channelopathy |
Nerve conduction study: typically normal unless severe muscle necrosis and atrophy are present [12]
| Finding | Significance |
|---|---|
| No decremental response at low-frequency stimulation | Rules out myasthenia gravis (where decremental response at 3 Hz is the hallmark) |
| No incremental response at high-frequency stimulation | Rules out Lambert-Eaton myasthenic syndrome (LEMS) |
| In PMC: may show initial increment followed by decrement after cooling | Reflects initial hyperexcitability (myotonia) then depolarisation block |
| Aspect | Detail |
|---|---|
| Gene tested | SCN4A (voltage-gated Na+ channel α-subunit, Nav1.4) [1] |
| Chromosome | 17q23 [1] |
| Method | Sanger sequencing of SCN4A coding exons, or next-generation sequencing (NGS) gene panel for skeletal muscle channelopathies (typically includes SCN4A, CLCN1, CACNA1S, KCNJ2, SCN5A, RYR1) |
| Expected finding | Heterozygous pathogenic/likely pathogenic missense variant in SCN4A (most commonly T1313M, R1448C/H, or other known PMC mutations in Domain III-IV linker or Domain IV S4 voltage sensor) |
| Interpretation | A known pathogenic SCN4A variant in a patient with compatible clinical phenotype = definitive diagnosis of PMC |
| Negative result | Does NOT rule out PMC — some variants may be in non-coding regions, or the variant may be novel/of uncertain significance (VUS). Clinical diagnosis remains valid if phenotype is classic |
| Additional testing | If SCN4A is negative, consider sequencing CLCN1 (myotonia congenita), CACNA1S (HypoK PP), KCNJ2 (Andersen-Tawil) |
Genetic testing: Identification of a gene mutation is diagnostic. Only ~50% positive for known mutation → negative genetic test has limited diagnostic value [13] — while this quote refers to LQTS, the principle applies to all channelopathies: a negative genetic test does not exclude the diagnosis if the clinical phenotype is characteristic.
Why Genetic Testing is the Gold Standard
Genetic testing is the gold standard because:
- It definitively identifies the molecular defect
- It distinguishes PMC from its allelic disorders (HyperK PP, SCM) — which share the same gene but have different mutations and phenotypes
- It enables family screening and genetic counselling (50% risk to offspring)
- It may guide pharmacogenomic treatment decisions in the future
- It avoids the need for invasive muscle biopsy (which is non-diagnostic in channelopathies anyway)
However, genetic testing has limitations:
- Not universally available (especially in Hong Kong, may need to send overseas)
- Turnaround time can be weeks to months
- Variants of uncertain significance (VUS) may be identified, complicating interpretation
- Novel mutations may not be in databases yet
Step 6: Other Investigations (Usually NOT Required but May Be Considered)
| Aspect | Detail |
|---|---|
| Role in PMC | Rarely indicated and usually NOT diagnostic |
| Typical findings | Non-specific or normal. May show type 2 fibre predominance, vacuolar changes in some cases, or tubular aggregates (non-specific finding seen in several channelopathies) |
| When to consider | Only if the diagnosis is uncertain after clinical assessment, EMG, and genetic testing — e.g., to exclude inflammatory myopathy, muscular dystrophy, or metabolic myopathy |
Muscle biopsy: done on weak but not atrophied muscle, guided by P/E, EMG ± MRI [14]. In PMC, muscle biopsy is almost never required because the diagnosis is made clinically and genetically.
| Aspect | Detail |
|---|---|
| Role in PMC | Limited utility; may show non-specific T2 hyperintensity (oedema) in affected muscles during or shortly after an attack |
| When useful | To exclude structural myopathies (dystrophy, inflammatory myopathy) when the diagnosis is uncertain |
| In inflammatory myopathy | MRI shows patchy ↑T2W indicating inflammation, oedema [14] — this pattern is NOT expected in PMC |
In historical and research settings, provocative tests have been used to confirm periodic paralysis:
| Test | Method | Expected in PMC | Caution |
|---|---|---|---|
| Oral/IV KCl loading | Administer KCl to raise serum K+ → observe for weakness | May provoke weakness (PMC is K+-sensitive) | Risk of arrhythmia — must be done under cardiac monitoring; rarely performed clinically today because genetic testing is available |
| Cold immersion test with EMG | As described above | Worsening myotonic discharges + CMAP decrement | Safe and informative; the preferred provocation test |
| Exercise test | Prolonged exercise followed by rest | May provoke myotonia or weakness | Less specific than cold provocation for PMC |
Dx of HyperK PP: weakness w/ mild hyperK, myotonia between attacks ± genetics ± provocative testing by KCl [1]. Provocative testing is the same principle for PMC but cold provocation is preferred.
| Investigation | PMC | Myotonia Congenita | HyperK PP | HypoK PP | TPP | Myotonic Dystrophy |
|---|---|---|---|---|---|---|
| Serum K+ (during attack) | Normal / ↑ | Normal | ↑ | ↓ | ↓↓ | Normal |
| TFT | Normal | Normal | Normal | Normal | Thyrotoxic | Normal |
| CK | Normal (mild ↑ peri-attack) | Normal | Normal (mild ↑) | Normal (mild ↑) | ↑ (mild) | Mildly ↑ |
| EMG: Myotonic discharges | +++ (↑↑ with cold) | +++ (↓ with warm-up) | + (between attacks) | − | − | ++ |
| EMG: CMAP after cooling | ↓↓ | ↓ (less dramatic) | ↓ | N/A | N/A | N/A |
| NCS | Normal | Normal | Normal | Normal | Normal | Normal |
| ECG | Normal (± mild hyperK changes) | Normal | HyperK changes | HypoK changes | HypoK changes | Conduction defects (1° AVB, bundle branch block) |
| Genetic test | SCN4A | CLCN1 | SCN4A | CACNA1S (70%) / SCN4A (10%) | Acquired (no genetic cause) | DMPK (CTG repeat) |
| Muscle biopsy | Non-specific / not done | Non-specific / not done | Non-specific / not done | Vacuolar changes | Non-specific | Characteristic dystrophic changes |
V. Key Points for Interpretation
The cooling EMG protocol is the most informative electrophysiological test for PMC. Here's what each finding means:
-
Increased myotonic discharges after cooling = The mutant Na+ channels have worsened inactivation kinetics in the cold → more persistent Na+ current → more membrane instability → more repetitive firing → more myotonic discharges. This proves that the myotonia is temperature-dependent, which is the hallmark of PMC.
-
Decreased CMAP amplitude after cooling = Prolonged cold has pushed many Na+ channels into a permanently inactivated state (depolarisation block) → fewer channels available to generate action potentials → the summed electrical output of the motor unit (CMAP) decreases → this is the electrophysiological equivalent of clinical weakness. The greater the CMAP decrement, the more severe the depolarisation block.
-
Recovery of CMAP after rewarming = As the muscle warms up, the channel kinetics improve → channels recover from inactivation → CMAP normalises → this correlates with the clinical recovery of strength after rewarming.
| Feature | PMC | Myotonia Congenita |
|---|---|---|
| Myotonic discharges at room temp | Present | Present |
| Effect of cooling | Dramatic increase in myotonic activity → then CMAP decrement (depolarisation block) | Modest increase in myotonic activity, minimal CMAP change |
| Effect of repeated voluntary contraction | Myotonic discharges worsen (paradoxical) | Myotonic discharges decrease (warm-up) |
| Transient weakness on EMG | Yes (CMAP decrement) | No (or minimal) |
High Yield Summary
- No formal classification criteria exist for PMC — diagnosis is clinical-genetic: characteristic phenotype (cold-induced paradoxical myotonia ± episodic weakness, AD inheritance, infantile onset, no systemic features) confirmed by SCN4A genetic testing
- Essential rule-out bloods: Serum K+ (during attack if possible), TFT (rule out TPP — critical in Asian populations), CK (rule out inflammatory myopathy/dystrophy)
- EMG is the key electrophysiological test: Look for myotonic discharges (dive-bomber sound) that worsen with cooling + CMAP amplitude decrement after cooling protocol
- Pseudomyotonia (hypothyroidism, Brody disease) is electrically silent on EMG — if no myotonic discharges, it is NOT PMC
- Genetic testing of SCN4A is the gold standard — identifies pathogenic variant (T1313M, R1448C/H most common). A negative test does not exclude the diagnosis if phenotype is classic
- Muscle biopsy is rarely needed — non-diagnostic for channelopathies; reserve for diagnostic uncertainty
- ECG is done to rule out electrolyte-related arrhythmia during attacks and to exclude Andersen-Tawil syndrome and myotonic dystrophy cardiac involvement
- NCS is normal in PMC — rules out neuropathic causes of weakness
Active Recall — Diagnosis & Investigations for Paramyotonia Congenita
References
[1] Senior notes: Ryan Ho Neurology.pdf, p.191–194 (Ion Channelopathies, Non-dystrophic myotonic syndromes, Periodic paralysis, Diseases of Muscles — investigations) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.134–145 (Approach to generalised weakness, investigations for peripheral hypotonia, myotonic dystrophy and causes of myotonia) [4] Senior notes: Ryan Ho Endocrine.pdf, p.29 (Thyrotoxic Periodic Paralysis — diagnosis) [5] Senior notes: Maksim Medicine Notes.pdf, p.95 (Thyrotoxic periodic paralysis — investigations) [9] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf, p.27 (Hypokalemia ECG changes and complications) [11] Senior notes: Ryan Ho Fundamentals.pdf, p.336 (Generalised weakness — investigation table for muscle diseases: CK, lactate, EMG, regional MRI, muscle biopsy) [12] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.709 (NCS in myositis — typically normal) [13] Senior notes: Ryan Ho Cardiology.pdf, p.196 (LQTS genetic testing — principle that negative test has limited diagnostic value) [14] Senior notes: Ryan Ho Rheumatology.pdf, p.92 (Myositis diagnosis — CK, EMG, muscle biopsy, MRI)
Management Algorithm & Treatment Modalities for Paramyotonia Congenita
Before diving into specifics, understand the overarching framework. PMC is a lifelong, genetic, non-curable skeletal muscle channelopathy. The management philosophy is therefore:
- There is no cure — you cannot fix the mutant SCN4A gene (yet)
- Management is symptomatic and preventive — reduce attack frequency and severity
- Avoid triggers — cold avoidance is the single most effective intervention
- Pharmacotherapy for myotonia — Na+ channel blockers to reduce the persistent Na+ current
- Acute attack management — rewarming + supportive care; rarely requires emergency intervention
- Genetic counselling — AD inheritance, 50% risk to offspring
- Multidisciplinary long-term follow-up — neurology-led with input from genetics, physiotherapy
Mx of non-dystrophic myotonic syndromes: procainamide, phenytoin, disopyramide, nifedipine, quinine sulphate [1]
This list from the notes represents the historical pharmacotherapy for myotonic disorders. In current practice (2024-2026), mexiletine has emerged as the first-line agent based on the highest quality evidence (the MYOMEX trial and others). We will cover both the lecture-based and current guideline-based approaches.
Detailed Treatment Modalities
These are the first-line interventions and should be implemented in every patient regardless of disease severity. Many patients with mild PMC can be managed with these alone.
| Measure | Rationale (From First Principles) | Practical Advice |
|---|---|---|
| Cold avoidance | Cold slows the already-impaired fast inactivation of mutant Nav1.4 → worsens persistent Na+ current → precipitates myotonia and weakness. Avoiding cold directly removes the primary trigger | Wear warm clothing in layers; use gloves and scarves in winter; avoid cold water immersion (swimming in cold water, handling ice); warm up the car before driving in winter; avoid air-conditioned rooms set too low |
| Gradual warm-up before activity | Abrupt vigorous exercise in the cold is a potent trigger. Gentle warm-up allows muscles to reach a stable temperature before demand is placed on them | Stretch and gently contract muscles before exercise; avoid sudden bursts of activity |
| Avoid K+-rich dietary load | Attacks of myotonia ↑ in hyperK [1] — elevated extracellular K+ further depolarises the already-vulnerable membrane. Dietary K+ load can transiently raise serum K+ | Moderate intake of bananas, oranges, potatoes, tomatoes, avocados; avoid K+ supplements unless specifically indicated |
| Avoid fasting | Fasting can mildly elevate serum K+ (insulin levels drop → less K+ driven into cells) and may provoke attacks in susceptible individuals | Regular meals; avoid prolonged fasting |
| Patient and family education | Understanding the disease empowers patients to anticipate and avoid triggers, recognise early symptoms, and know when to seek help | Provide written information; connect with patient support groups (e.g., Periodic Paralysis International, Myotonia UK) |
| Alert card / medical ID | In emergencies (e.g., anaesthesia, hospital admission), healthcare providers need to know about the channelopathy to avoid triggering agents | Carry a medical alert card/bracelet stating "Paramyotonia Congenita — SCN4A channelopathy — avoid cold, succinylcholine, and K+ loading" |
| Physiotherapy | Maintain muscle strength and flexibility; graded exercise programme to prevent deconditioning while avoiding trigger situations | Regular, moderate exercise in warm environments; avoid eccentric exercise in the cold |
Cold Avoidance is the Most Effective Treatment
No drug can match the efficacy of simply avoiding cold. Many patients with mild PMC require no pharmacotherapy at all if they can adequately manage their cold exposure. This is a disease where lifestyle modification is genuinely therapeutic, not just adjunctive.
B. Pharmacotherapy — First-Line: Mexiletine
- Drug class: Class IB antiarrhythmic — a use-dependent sodium channel blocker
- Name breakdown: "Mex-i-le-tine" — an oral analogue of lidocaine (lignocaine); "mex" is arbitrary, but think of it as "methylated lixocaine-like antine"
- Mechanism in PMC: Mexiletine preferentially binds to and blocks inactivated Na+ channels — i.e., the very channels that are stuck in the abnormally persistent open/re-opening state due to the SCN4A mutation. By blocking these dysfunctional channels, mexiletine reduces the persistent Na+ current → stabilises the membrane → reduces myotonia
The MYOMEX trial (2012, Neurology) — a landmark randomised, double-blind, placebo-controlled crossover trial — demonstrated that mexiletine significantly reduced:
- Stiffness severity (VAS score)
- Clinical myotonia (grip relaxation time)
- EMG myotonic discharge duration
This was the first high-quality RCT evidence for any anti-myotonic drug and established mexiletine as the evidence-based first-line treatment for non-dystrophic myotonia (including PMC).
| Aspect | Detail |
|---|---|
| Dose | Start 150 mg once daily, uptitrate gradually to 150-200 mg TDS (three times daily). Maximum 1200 mg/day (rarely needed) |
| Route | Oral |
| Onset of action | Hours to days; full effect within 1-2 weeks |
| Monitoring | ECG before starting and periodically (QTc, PR interval, QRS duration) — mexiletine is a Na+ channel blocker and can prolong conduction; LFTs (hepatic metabolism); CBC (rare blood dyscrasias) |
| Side effects | GI (nausea, dyspepsia — most common, often dose-limiting), tremor, dizziness, cardiac conduction abnormalities (bradycardia, heart block, QT prolongation in susceptible individuals) |
| Contraindications | Pre-existing cardiac conduction disease (2nd/3rd degree AV block, sick sinus syndrome without pacemaker); cardiogenic shock; known hypersensitivity; hepatic failure (metabolised by CYP1A2 and CYP2D6) |
Why does mexiletine work specifically in PMC? The answer lies in its use-dependent and state-dependent binding:
- Use-dependent: The more the channel opens and inactivates, the more mexiletine binds → in PMC, the mutant channels are cycling through open/inactivated states more often than normal → mexiletine preferentially accumulates in these hyperactive channels
- State-dependent: Mexiletine has higher affinity for the inactivated state of the Na+ channel than the resting state → since PMC channels spend abnormally long in the inactivated (or failing-to-inactivate) state, mexiletine binds them more effectively
- The net effect: mexiletine "plugs" the leaky channels → reduces persistent Na+ current → membrane stabilisation → less myotonia
Exam Pearl — Why Mexiletine, Not Just Any Na+ Channel Blocker?
Mexiletine is a Class IB antiarrhythmic (like lidocaine). Class IB agents have fast on-off kinetics — they bind and unbind quickly. This means they preferentially block channels that are firing rapidly or abnormally (as in myotonia) while having minimal effect on channels firing normally. This is why mexiletine reduces myotonia without causing significant weakness in normal muscles. In contrast, Class IC agents (flecainide) have slow off-kinetics and could cause excessive block of normal channels → more side effects.
C. Pharmacotherapy — Second-Line Agents
If mexiletine is ineffective, poorly tolerated, or contraindicated, several second-line agents can be considered:
| Aspect | Detail |
|---|---|
| Drug class | Anticonvulsant — Na+ channel blocker (voltage-gated) |
| Mechanism | Blocks voltage-gated Na+ channels in a use-dependent manner (similar principle to mexiletine but different binding site). Also inhibits glutamate release |
| Dose | Start 25 mg/day, slow uptitration over weeks to 100-400 mg/day (must titrate slowly due to risk of Stevens-Johnson syndrome) |
| Evidence | Open-label studies show benefit in non-dystrophic myotonia; a small RCT (Andersen et al., 2017) showed benefit in myotonic dystrophy type 1 |
| Side effects | Rash (including Stevens-Johnson syndrome/TEN — must uptitrate slowly), dizziness, diplopia, headache, ataxia |
| Contraindications | Known hypersensitivity; caution in hepatic impairment; avoid rapid dose escalation |
| Advantage | Good tolerability profile if uptitrated slowly; familiar to most neurologists |
| Aspect | Detail |
|---|---|
| Drug class | Anticonvulsant — Na+ channel blocker |
| Mechanism | Stabilises inactivated state of Na+ channels → reduces repetitive firing |
| Dose | 200-1200 mg/day in divided doses |
| Side effects | Dizziness, ataxia, diplopia, hyponatraemia (SIADH), aplastic anaemia (rare), hepatotoxicity, SJS/TEN (especially in HLA-B*1502 carriers — important in Hong Kong Chinese population) |
| Pre-prescription screening | HLA-B1502 screening before carbamazepine in Han Chinese* — this is a pharmacogenomic consideration critical in Hong Kong [15] |
| Advantage | Long clinical experience; readily available |
HLA-B*1502 Screening Before Carbamazepine — Hong Kong Relevance
In Hong Kong, where the population is predominantly Han Chinese, the prevalence of HLA-B*1502 is approximately 8%. This allele is strongly associated with carbamazepine-induced SJS/TEN. Always screen before prescribing carbamazepine. If positive, carbamazepine is contraindicated — use an alternative agent. This applies equally to oxcarbazepine.
Mx of non-dystrophic myotonic syndromes: procainamide, phenytoin, disopyramide, nifedipine, quinine sulphate [1]
| Aspect | Detail |
|---|---|
| Drug class | Anticonvulsant — Na+ channel blocker |
| Mechanism | Stabilises inactivated state of Na+ channels; very similar principle to mexiletine and carbamazepine |
| Dose | 100-300 mg/day |
| Side effects | Gingival hyperplasia, hirsutism, coarsening of facial features, cerebellar ataxia (with chronic use/toxicity), peripheral neuropathy, hepatotoxicity, SJS/TEN, osteomalacia |
| Limitations | Narrow therapeutic index; zero-order kinetics (small dose changes can cause disproportionate changes in serum levels); cosmetically undesirable side effects in young patients → less favoured in current practice |
| Current status | Largely superseded by mexiletine and lamotrigine due to side effect profile, but remains an option if others are unavailable or contraindicated |
| Aspect | Detail |
|---|---|
| Drug class | Carbonic anhydrase (CA) inhibitor — "acet-azolamide" = acetyl group + azolamide (heterocyclic sulfonamide) |
| Mechanism | Complex and not fully understood for channelopathies. Proposed mechanisms: (1) Mild metabolic acidosis from renal HCO₃⁻ wasting → intracellular acidification → modifies Na+ channel gating favourably; (2) Opens Ca²+-activated K+ channels → membrane hyperpolarisation → counteracts the persistent Na+ current; (3) Reduces intracellular Na+ accumulation |
| Dose | 250-1000 mg/day in divided doses |
| Indication in PMC | Particularly useful when the periodic paralysis component is dominant (i.e., episodic weakness > myotonia). Acetazolamide is the standard prophylactic agent for primary hypokalemic periodic paralysis and can benefit the weakness component of PMC |
| Side effects | Paraesthesiae (especially perioral and digital — due to metabolic acidosis), renal stones (due to alkaline urine), hypokalaemia, fatigue, GI upset, metabolic acidosis |
| Contraindications | Sulfonamide allergy; severe hepatic/renal impairment; adrenocortical insufficiency |
| Caution | In some SCN4A channelopathies, acetazolamide can paradoxically worsen myotonia (particularly in certain HyperK PP mutations). Therefore, a therapeutic trial with close monitoring is advisable. If symptoms worsen, discontinue |
Mx of primary HypoK PP: oral KCl (acute) + acetazolamide (CA inhibitor, prophylactic) [1]
| Agent | Class | Notes |
|---|---|---|
| Procainamide | Class IA antiarrhythmic (Na+ channel blocker) | Listed in lecture notes [1]; effective but rarely used today due to risk of drug-induced lupus (anti-histone antibodies) and agranulocytosis with chronic use |
| Disopyramide | Class IA antiarrhythmic | Listed in lecture notes [1]; effective anti-myotonic agent but significant anticholinergic side effects (urinary retention, dry mouth, constipation) and negative inotropic effect → avoid in heart failure |
| Quinine sulphate | Anti-malarial with Na+ channel blocking properties | Listed in lecture notes [1]; formerly used for myotonia and cramps; now largely abandoned due to narrow therapeutic index and risk of cardiac arrhythmia (QT prolongation), thrombocytopenia, and cinchonism |
| Nifedipine | Dihydropyridine Ca²+ channel blocker | Listed in lecture notes [1]; mechanism in myotonia is unclear (may modify Ca²+-dependent processes in muscle membrane); limited evidence; rarely used in current practice |
| Ranolazine | Late Na+ current inhibitor (antianginal) | Emerging evidence; selectively blocks the late/persistent Na+ current (exactly the defect in PMC). Theoretical advantage: targets the pathological current more specifically than mexiletine. Limited clinical data in PMC; used in specialist centres |
| Flecainide | Class IC antiarrhythmic | Potent Na+ channel blocker; can be effective but has slow off-kinetics → risk of proarrhythmia, especially in structural heart disease. Reserved for refractory cases under specialist supervision with cardiac monitoring |
Acute attacks of PMC (typically cold-induced myotonia progressing to flaccid weakness) are usually self-limiting and resolve with rewarming. However, severe attacks may require monitoring.
| Step | Action | Rationale |
|---|---|---|
| 1. Rewarming | Move patient to a warm environment; apply warm blankets; warm fluids | Directly reverses the cold-induced worsening of Na+ channel inactivation. As the muscle warms, channel kinetics improve → persistent Na+ current decreases → membrane re-stabilises → strength returns |
| 2. Rest | Avoid further muscle activity until weakness resolves | Further contraction of already-depolarised muscles will worsen the paradoxical myotonia and may deepen the depolarisation block |
| 3. Cardiac monitoring | Continuous ECG if weakness is severe or prolonged | Although PMC attacks rarely cause dangerous arrhythmias (unlike TPP with severe hypoK), monitoring is prudent because: mild hyperK can occur → peaked T waves, bradycardia in severe cases |
| 4. Check serum K+ | During the attack if possible | Expected: normal or mildly elevated. If severely low → reconsider diagnosis (TPP? HypoK PP?). If elevated → electrolyte management as needed |
| 5. K+ replacement | Usually NOT needed in PMC (unlike TPP/HypoK PP) | Total body K+ is normal in PMC — the pathology is the Na+ channel, not a K+ shift. Giving K+ to a PMC patient with normal/elevated K+ would worsen the attack (attacks ↑ in hyperK [1]). Only replace K+ if documented hypokalemia from a separate cause |
| 6. IV mexiletine (if available) | Rarely needed; can be considered in severe/prolonged attacks refractory to rewarming | Provides rapid Na+ channel blockade. Limited availability; most attacks resolve spontaneously |
Critical Difference from TPP/HypoK PP — Do NOT Give K+ Empirically!
In thyrotoxic periodic paralysis and hypokalemic periodic paralysis, K+ replacement accelerates recovery. In PMC, the K+ is normal or high — giving K+ will worsen the attack by further depolarising the membrane. Attacks of myotonia ↑ in hyperK, ↓ by hypoK [1]. Always check the serum K+ before deciding whether to replace.
This is a critical safety issue that must be communicated to anaesthetists before any surgical procedure.
| Agent/Situation | Risk in PMC | Action |
|---|---|---|
| Succinylcholine (suxamethonium) | Depolarising neuromuscular blocker → causes initial depolarisation of all muscle fibres. In PMC, this triggers massive persistent Na+ current in mutant channels → severe sustained contraction (masseter spasm, generalised rigidity) that may mimic malignant hyperthermia | ABSOLUTELY CONTRAINDICATED in PMC. Use non-depolarising agents (e.g., rocuronium, cisatracurium) instead |
| Hypothermia during surgery | Operating theatres are cold; body temperature drops under general anaesthesia → can trigger severe myotonia and weakness intra/post-operatively | Maintain normothermia: use warm IV fluids, forced-air warming blankets, heated operating theatre |
| Cold IV fluids | Direct muscle cooling → trigger | Use warmed IV fluids |
| K+-containing IV fluids | Elevated K+ worsens the channel defect | Avoid Ringer's lactate/Hartmann's (contains K+); use normal saline or dextrose-saline |
| Malignant hyperthermia risk | PMC is caused by SCN4A mutations, NOT RYR1 mutations. Therefore, PMC patients are NOT at increased risk of true malignant hyperthermia (which is a Ca²+ channel/ryanodine receptor disorder). However, succinylcholine-triggered rigidity in PMC can clinically mimic MH | Clarify to anaesthetists: PMC patients are not MH-susceptible per se, but succinylcholine is still contraindicated because it triggers myotonic rigidity (which may be mistaken for MH). Volatile anaesthetics (e.g., sevoflurane) are generally safe in PMC (unlike in true MH susceptibility) |
Malignant hyperthermia: RYR1 or DHP mutation → unregulated Ca²+ influx from SR → sustained muscle contraction → ↑↑metabolism → metabolic acidosis, rhabdomyolysis, hyperthermia. Triggered by anaesthetic agents (e.g., halothane, isoflurane) [1]. This is a different condition from PMC.
Anaesthetic Safety Card for PMC
Every PMC patient should carry information stating:
- Avoid: Succinylcholine, hypothermia, K+-containing fluids
- Safe: Non-depolarising neuromuscular blockers, volatile agents (NOT an MH risk), propofol, opioids
- Ensure: Active warming, temperature monitoring, warm IV fluids
| Aspect | Detail |
|---|---|
| Inheritance | Autosomal dominant → each child of an affected parent has a 50% chance of inheriting the mutation |
| Penetrance | High (most carriers manifest symptoms, though severity varies) |
| Predictive testing | Can be offered to at-risk family members (children, siblings) via SCN4A genetic testing |
| Prenatal/preimplantation | Technically possible (PGD/PND for known familial SCN4A mutation) but rarely requested because PMC is a non-life-threatening condition with manageable symptoms |
| Reproductive counselling | Discuss the 50% transmission risk, the nature of the disease (lifelong but manageable, non-progressive), and available treatments |
| Aspect | Frequency | Purpose |
|---|---|---|
| Neurology review | Every 6-12 months (or as needed) | Assess symptom control, medication efficacy and side effects, functional status |
| ECG | Before starting mexiletine/other Na+ channel blockers; then every 6-12 months | Monitor for QT prolongation, conduction abnormalities (PR prolongation, QRS widening) |
| LFTs | Every 6-12 months if on mexiletine | Hepatic metabolism; monitor for drug-induced hepatotoxicity |
| Serum K+ | As needed (during attacks, or periodically) | Ensure electrolyte stability; guide acute management |
| Muscle strength assessment | Annually | Some PMC patients develop mild fixed proximal weakness in later decades (4th-6th decade) from cumulative myofibre damage |
| Quality of life assessment | Annually | PMC can significantly impact daily activities, occupational function, and psychological well-being |
| Line | Treatment | Indication | Key Points |
|---|---|---|---|
| All patients | Cold avoidance + lifestyle modification + education + genetic counselling | Universal | Most important intervention; sufficient for mild disease |
| 1st line | Mexiletine 150-200 mg TDS | Myotonia affecting quality of life despite non-pharmacological measures | Best evidence (MYOMEX trial); ECG monitoring required; GI side effects common |
| 2nd line | Lamotrigine / Carbamazepine / Phenytoin | Mexiletine intolerant or ineffective | HLA-B*1502 screening before CBZ in HK; lamotrigine requires slow uptitration |
| 2nd line (weakness-dominant) | Acetazolamide | Periodic paralysis component dominant | Can paradoxically worsen some SCN4A mutations → trial with monitoring |
| 3rd line | Combination therapy or specialist agents (ranolazine, flecainide) | Refractory to monotherapy | Specialist neuromuscular centre; cardiac monitoring essential |
| Acute attack | Rewarming + rest + cardiac monitoring | During attack | Do NOT give K+ empirically (unlike TPP) |
| Perioperative | Avoid succinylcholine + maintain normothermia + avoid K+ fluids | Any surgery/anaesthesia | Alert card; communicate with anaesthetist |
High Yield Summary
- PMC is incurable but manageable — management is symptomatic and preventive
- Cold avoidance is the single most effective intervention — many mild patients need no drugs
- Mexiletine (Class IB Na+ channel blocker) is the first-line pharmacotherapy — use-dependent block of inactivated Na+ channels reduces persistent Na+ current and myotonia. ECG monitoring required
- Second-line agents: lamotrigine, carbamazepine (HLA-B1502 screen in HK!), phenytoin, acetazolamide* (especially for weakness-dominant phenotype)
- Historical agents from lecture notes: procainamide, phenytoin, disopyramide, nifedipine, quinine sulphate [1] — mostly superseded by mexiletine in current practice
- Acute attacks: Rewarming + rest; cardiac monitoring if severe. Do NOT give K+ (unlike TPP/HypoK PP — K+ worsens PMC)
- Anaesthetic safety: Succinylcholine is CONTRAINDICATED (triggers myotonic rigidity mimicking MH). Use non-depolarising agents. Maintain normothermia. Avoid K+-containing fluids
- PMC is NOT malignant hyperthermia (SCN4A ≠ RYR1) — volatile anaesthetics are safe, but succinylcholine is not
- Genetic counselling: AD inheritance, 50% risk to offspring, high penetrance. Offer predictive testing to at-risk relatives
- Long-term monitoring: ECG + LFTs on mexiletine; muscle strength annually; QoL assessment
Active Recall — Management of Paramyotonia Congenita
References
[1] Senior notes: Ryan Ho Neurology.pdf, p.191–194 (Non-dystrophic myotonic syndromes management: procainamide, phenytoin, disopyramide, nifedipine, quinine sulphate; Ion channelopathies; Periodic paralysis management; Malignant hyperthermia) [4] Senior notes: Ryan Ho Endocrine.pdf, p.29 (Thyrotoxic Periodic Paralysis management — K+ replacement in TPP context) [9] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf, p.27 (Hypokalemia complications and ECG changes) [15] Senior notes: Learning_Points_All_Lectures.txt (HLA-B5801 screening principle; pharmacogenomics in Han Chinese — extended to HLA-B1502 for carbamazepine by analogy)
Complications of Paramyotonia Congenita
Paramyotonia congenita is generally considered a benign, non-life-threatening condition — especially compared to other neuromuscular diseases like muscular dystrophies or inflammatory myopathies. However, "benign" does not mean "without complications." Several important complications can arise from the disease itself, from its treatment, and from the impact on daily life. Understanding these complications requires tracing each one back to the underlying pathophysiology.
| Category | Complications |
|---|---|
| Direct consequences of myotonia | Functional impairment, falls and injury, cold-weather disability |
| Direct consequences of periodic paralysis | Acute immobility, cardiac arrhythmia (rare), aspiration risk (very rare) |
| Long-term muscle consequences | Late-onset fixed proximal myopathy |
| Anaesthetic complications | Succinylcholine-triggered rigidity mimicking malignant hyperthermia, intra-/post-operative hypothermic attacks |
| Treatment-related complications | Mexiletine cardiac side effects, carbamazepine SJS/TEN, acetazolamide renal stones |
| Psychosocial complications | Occupational limitation, psychological impact, social isolation |
| Pregnancy-related | Neonatal transient myotonia, peripartum attack risk |
Pathophysiological basis: The persistent Na+ current through mutant Nav1.4 channels causes delayed muscle relaxation (myotonia), which worsens with cold and repeated contraction (paradoxical). This directly translates to difficulty with everyday motor tasks.
| Functional Impact | Mechanism | Clinical Scenario |
|---|---|---|
| Difficulty releasing grip | Myotonia of hand flexors → cannot let go of objects | Unable to release a doorknob, drop tools at work, unable to let go after a handshake |
| Difficulty opening eyes | Myotonia of orbicularis oculi → lids "lock" shut after forceful closure | Blinking in cold wind → eyes get stuck shut → dangerous when driving, cycling, or crossing roads |
| Dysarthria / speech difficulty | Myotonia of tongue and perioral muscles | Slurred speech after cold exposure; difficulty eating or drinking cold items |
| Gait stiffness and falls | Myotonia of lower limb muscles → stiff, slow gait → inability to adjust foot placement quickly | Falls on cold days, especially on uneven surfaces; difficulty with stairs in winter |
| Impaired fine motor tasks | Hand myotonia → clumsiness | Difficulty typing, writing, using chopsticks/utensils (particularly relevant in Hong Kong's cold, air-conditioned office environments) |
Why this matters: Although PMC is "non-progressive" in terms of the underlying channel defect, the functional disability can be significant. Patients may avoid outdoor activities in cold weather, limiting exercise, socialisation, and occupational capacity.
2. Complications of Episodic Weakness (Periodic Paralysis)
When myotonia progresses to depolarisation block, the patient develops episodic flaccid weakness. Most attacks are self-limiting, but complications can occur:
- During the transition from myotonia → weakness, there is a window where the patient's legs may suddenly "give way"
- If walking or on stairs when weakness strikes, the patient can fall and sustain injuries (fractures, head trauma)
- Pathophysiological basis: The shift from mild depolarisation (myotonia, where muscles are stiff but contracted) to severe depolarisation (depolarisation block, where muscles are flaccid) can occur relatively abruptly, especially with sudden cold exposure
- During severe attacks, serum K+ may be mildly elevated (due to K+ efflux from depolarised muscle cells)
- Cardiac arrhythmia, particularly when K+ < 2.0 [9] — this applies to hypoK states; for PMC, the concern is the opposite direction. Mild hyperK can cause:
- Peaked T waves
- Bradycardia
- Very rarely, more serious arrhythmias
- However, clinically significant cardiac arrhythmia from PMC attacks is extremely rare because:
- The hyperK is usually mild and transient
- The cardiac Na+ channel (SCN5A, Nav1.5) is a different isoform from the skeletal muscle channel (SCN4A, Nav1.4) — PMC mutations affect Nav1.4, not Nav1.5, so the heart's electrical system is not directly affected by the genetic defect
- Cardiac monitoring is recommended during severe attacks out of caution, not because arrhythmia is expected
PMC Does NOT Cause Intrinsic Cardiac Disease
Unlike myotonic dystrophy (which causes cardiomyopathy and conduction defects) or inherited cardiac channelopathies like Brugada syndrome or LQTS (which involve the cardiac Na+ channel SCN5A), PMC affects a skeletal muscle-specific channel (SCN4A). The heart itself is structurally and electrically normal in PMC. Any cardiac risk is secondary to transient electrolyte disturbance during severe attacks, not primary cardiac involvement.
- Usually spares respiratory and bulbar muscles [1] — this is true for most attacks
- However, in extremely severe attacks (very rare), diaphragmatic and intercostal weakness could theoretically impair ventilation
- This is far more of a concern in hyperkalemic periodic paralysis (where attacks can be more severe) than in PMC
- Practical point: if a PMC patient presents with respiratory difficulty during an attack, it is more likely due to cold-induced bronchospasm or an intercurrent illness than the PMC itself
This is the most clinically significant long-term complication of PMC.
What happens:
- Some PMC patients develop mild, fixed (permanent) proximal weakness in the 4th to 6th decades of life
- This weakness is present between attacks and does not fluctuate with temperature
May develop progressive proximal myopathy after attacks subside in 4th to 6th decades [1] — while this quote refers to HyperK PP, the same phenomenon occurs in PMC as an allelic SCN4A disorder
Pathophysiological basis — why does a "functional" channelopathy cause structural muscle damage over decades?
- Repeated depolarisation block → during each attack, muscle fibres experience prolonged depolarisation and electrical inexcitability
- Calcium overload → persistent Na+ current raises intracellular Na+; this drives the Na+/Ca²+ exchanger in reverse, importing Ca²+ into the cell. Over time, repeated Ca²+ overload activates calpains (Ca²+-dependent proteases) → myofibre damage
- Osmotic stress → persistent Na+ entry draws water into muscle cells (osmotic gradient) → cell swelling → vacuolar changes on biopsy
- Cumulative myofibre loss → over decades, repeated micro-damage depletes the regenerative capacity of satellite cells → permanent loss of functional muscle fibres → fixed weakness
- Muscle biopsy findings (when performed in older patients with fixed weakness): may show vacuolar myopathy, tubular aggregates, and/or mild fibrosis — these are the histological footprints of chronic channel dysfunction
Clinical significance:
- The fixed myopathy is usually mild (MRC grade 4-4+/5 proximally) and does not cause severe disability
- However, it adds to the burden of the disease in middle-aged and older patients
- It is not reversible — once myofibres are lost, they cannot be regenerated
- Aggressive early treatment of myotonia (mexiletine, cold avoidance) may theoretically reduce the cumulative muscle damage, though this has not been proven in clinical trials
4. Anaesthetic Complications
This is a critical safety issue — the most dangerous scenario for a PMC patient is an uninformed anaesthetist.
| Aspect | Detail |
|---|---|
| Mechanism | Succinylcholine (suxamethonium) is a depolarising neuromuscular blocker → causes initial depolarisation of all skeletal muscle fibres. In PMC, this triggers massive persistent Na+ current through the mutant Nav1.4 channels → severe, sustained muscle contraction (generalised rigidity, particularly masseter spasm) that does NOT respond to additional succinylcholine or non-depolarising agents initially |
| Clinical presentation | Generalised rigidity, masseter spasm ("jaws of steel"), hyperthermia from sustained muscle contraction, elevated CK, rhabdomyolysis → clinically mimics malignant hyperthermia (MH) |
| Why it is NOT true MH | True MH is caused by RYR1 or DHPR mutations → unregulated Ca²+ release from sarcoplasmic reticulum. PMC is caused by SCN4A → persistent Na+ influx. The clinical presentation overlaps but the molecular mechanism is different. Dantrolene (which blocks RyR1 Ca²+ release) may or may not help in PMC-triggered rigidity because the primary defect is Na+ influx, not Ca²+ release |
| Prevention | Avoid succinylcholine in ALL PMC patients. Use non-depolarising agents (rocuronium, cisatracurium). If emergency intubation is needed without alternatives, be prepared for potential rigidity |
Malignant hyperthermia: RYR1 or DHP mutation → unregulated Ca²+ influx from SR → sustained muscle contraction → ↑↑ metabolism → metabolic acidosis, rhabdomyolysis, hyperthermia. Triggered by anaesthetic agents (e.g., halothane, isoflurane) [1]
| Aspect | Detail |
|---|---|
| Mechanism | Operating theatres are cold (typically 18-22°C); body temperature drops during prolonged anaesthesia; cold IV fluids further cool the patient → triggers severe myotonia ± weakness during or after surgery |
| Consequences | Post-operative inability to move, breathe adequately, or maintain airway; potential delayed extubation; rhabdomyolysis from sustained contraction |
| Prevention | Active warming (forced-air blankets, warmed IV fluids, temperature monitoring), avoid cold irrigating fluids intra-operatively, raise theatre temperature |
- Can occur during severe or prolonged attacks, or after succinylcholine exposure
- Mechanism: Sustained muscle contraction (myotonia) or depolarisation block → muscle fibre breakdown → release of myoglobin, CK, K+, lactate, and other intracellular contents into the bloodstream
Consequences of rhabdomyolysis:
| Complication | Mechanism |
|---|---|
| Acute kidney injury (AKI) | Myoglobin precipitates in renal tubules (especially in acidic urine) → tubular obstruction and direct nephrotoxicity |
| Hyperkalaemia | K+ released from damaged muscle → further worsens the PMC channel defect (vicious cycle) + cardiac arrhythmia risk |
| Metabolic acidosis | Lactic acid from ischaemic/damaged muscle; impaired renal acid excretion if AKI develops |
| Disseminated intravascular coagulation (DIC) | Rare; massive tissue factor release from severely damaged muscle |
Clinical indicators: CK > 5× upper limit of normal; dark ("cola-coloured") urine (myoglobinuria); elevated creatinine; positive urine dipstick for blood but no RBCs on microscopy (because dipstick detects myoglobin as well as haemoglobin)
In PMC context: Severe rhabdomyolysis is uncommon because most attacks are short-lived and self-limiting. It is more of a risk in:
- Prolonged, severe cold exposure
- Anaesthetic complications (succinylcholine)
- Failure to rewarm promptly
6. Treatment-Related Complications
Each pharmacological agent used in PMC carries its own adverse effect profile, which should be monitored as part of long-term management.
| Complication | Mechanism | Monitoring |
|---|---|---|
| GI intolerance (nausea, dyspepsia) | Direct GI irritation; most common side effect; often dose-limiting | Take with food; dose reduction if intolerable |
| Cardiac conduction abnormalities | Mexiletine is a Class IB Na+ channel blocker → excessive block of cardiac Na+ channels (Nav1.5) can prolong QRS, PR interval, and rarely QT → risk of bradycardia, heart block, proarrhythmia | ECG before starting and periodically (every 6-12 months); avoid in pre-existing conduction disease |
| Hepatotoxicity | Hepatic metabolism (CYP1A2, CYP2D6); rare but reported | LFTs every 6-12 months |
| Tremor, dizziness | CNS effects of Na+ channel blockade in the brain | Dose-dependent; usually mild |
| Complication | Mechanism | Prevention |
|---|---|---|
| Stevens-Johnson Syndrome / TEN | HLA-B1502-associated hypersensitivity reaction; ~8% carrier rate in Han Chinese* [15] | HLA-B1502 screening before prescription in Hong Kong*; if positive, carbamazepine is contraindicated |
| Hyponatraemia (SIADH) | Carbamazepine enhances ADH effect on renal collecting ducts → water retention | Monitor serum Na+, especially in elderly |
| Aplastic anaemia (rare) | Idiosyncratic bone marrow suppression | CBC monitoring |
| Complication | Mechanism | Prevention |
|---|---|---|
| Renal stones | CA inhibition → alkaline urine → calcium phosphate/carbonate stone precipitation | Adequate hydration; monitor for renal colic symptoms |
| Metabolic acidosis | Renal HCO₃⁻ wasting (intended mechanism of action, but can become excessive) | Monitor serum HCO₃⁻ |
| Paraesthesiae | Metabolic acidosis affecting nerve function; especially perioral and digital | Dose-dependent; usually tolerable |
| Hypokalaemia | Renal K+ wasting (kaliuretic effect of carbonic anhydrase inhibition in proximal tubule) | Monitor K+; paradoxically may help the myotonia (since attacks ↓ by hypoK [1]) but could worsen periodic paralysis if HypoK PP component exists |
| Paradoxical worsening | In certain SCN4A mutations, acetazolamide can worsen myotonia through incompletely understood mechanisms | Therapeutic trial with monitoring; discontinue if symptoms worsen |
These are often underappreciated but can be the most significant burden for patients living with PMC.
| Complication | Explanation |
|---|---|
| Occupational limitation | Patients may be unable to work in cold environments (e.g., outdoor construction, cold storage, fisheries — relevant in Hong Kong). Occupations requiring fine motor dexterity in cold conditions (e.g., surgery, dentistry, food handling) may be affected |
| Social isolation | Avoidance of winter outdoor activities, sports, swimming → reduced social participation; embarrassment about "locking up" in public (e.g., unable to release a handshake) |
| Anxiety and depression | Living with a chronic, unpredictable, visible condition (stiffness episodes in public); frustration with functional limitations; fear of attacks. Studies on non-dystrophic myotonias show significantly impaired quality of life and higher rates of anxiety/depression compared to healthy controls |
| Impact on children | PMC typically manifests in infancy/childhood; children may be teased or unable to participate in winter sports and playground activities; school performance may be affected if hands are too stiff to write during cold mornings |
| Genetic burden | Knowledge of AD inheritance and 50% transmission risk can cause significant anxiety about family planning |
PMC is not a contraindication to pregnancy, but several considerations arise:
| Issue | Detail |
|---|---|
| Attack frequency during pregnancy | Variable — some women report worsening (possibly due to hormonal fluctuations and fluid shifts), others report no change |
| Medication safety | Mexiletine: limited human pregnancy data; generally considered relatively safe (Class C) but should be used only if benefits outweigh risks. Carbamazepine: teratogenic (neural tube defects) — avoid in pregnancy. Lamotrigine: considered relatively safer among anticonvulsants but requires dose adjustment |
| Labour and delivery | Cold operating theatres during caesarean section can trigger attacks → ensure active warming. Regional anaesthesia (epidural/spinal) is generally safe and preferred over general anaesthesia (avoids succinylcholine risk). Inform the obstetric anaesthetist about the channelopathy |
| Neonatal | AD inheritance → 50% chance the baby inherits the SCN4A mutation. Affected neonates may show signs of myotonia from birth (stiffness on crying, feeding difficulties from facial/tongue myotonia). Neonatal genetic testing can be offered |
| Complication | Frequency | Severity | Preventability |
|---|---|---|---|
| Functional impairment (myotonia) | Very common | Mild-moderate | High (cold avoidance + mexiletine) |
| Falls and injury | Common | Variable | Moderate (awareness, environment) |
| Late-onset fixed myopathy | Common (4th-6th decade) | Mild | Unknown (possibly reduced by early treatment) |
| Cardiac arrhythmia during attack | Rare | Potentially serious | High (monitoring during severe attacks) |
| Succinylcholine crisis | Rare (only if exposed) | Severe | Completely preventable (avoidance) |
| Hypothermic perioperative attack | Uncommon | Moderate-severe | High (active warming, anaesthetist communication) |
| Rhabdomyolysis | Rare | Moderate-severe | Moderate (prompt rewarming, avoid triggers) |
| Respiratory compromise | Extremely rare | Severe | Low (unpredictable) |
| Mexiletine cardiac effects | Uncommon | Moderate | High (ECG monitoring) |
| Carbamazepine SJS/TEN | Rare (high if HLA-B*1502+) | Severe-fatal | Completely preventable (HLA screening) |
| Psychosocial impact | Common | Mild-severe | Moderate (support, counselling, patient groups) |
High Yield Summary
- PMC is a non-life-threatening but functionally significant condition — the main complications are related to functional impairment, late-onset myopathy, anaesthetic risks, and psychosocial burden
- Late-onset fixed proximal myopathy (4th-6th decade) is the most important long-term musculoskeletal complication — caused by cumulative myofibre damage from repeated depolarisation episodes and Ca²+ overload. It is irreversible
- Anaesthetic complications are the most dangerous and most preventable — succinylcholine is absolutely contraindicated (triggers myotonic rigidity mimicking MH); hypothermia must be avoided perioperatively
- PMC does NOT cause intrinsic cardiac disease (unlike myotonic dystrophy) — SCN4A (skeletal Nav1.4) ≠ SCN5A (cardiac Nav1.5). Cardiac risk is only from transient electrolyte disturbance during severe attacks
- Rhabdomyolysis is rare but can occur with prolonged severe attacks or succinylcholine exposure → monitor CK, renal function, urine myoglobin
- Treatment complications must be monitored: mexiletine → ECG (cardiac conduction); carbamazepine → HLA-B1502 screening in Hong Kong* (SJS/TEN risk); acetazolamide → renal stones, metabolic acidosis, paradoxical worsening possible
- Psychosocial impact is common and underappreciated — occupational limitation, social isolation, anxiety/depression; offer counselling and connect with support groups
- Pregnancy is not contraindicated but requires medication review (avoid carbamazepine), active warming during delivery, anaesthetist communication, and neonatal genetic counselling
Active Recall — Complications of Paramyotonia Congenita
References
[1] Senior notes: Ryan Ho Neurology.pdf, p.191–194 (Ion Channelopathies; Periodic paralysis — late-onset myopathy; Non-dystrophic myotonic syndromes; Malignant hyperthermia — RYR1 mechanism) [9] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf, p.27 (Hypokalemia complications including cardiac arrhythmia, rhabdomyolysis) [15] Senior notes: Learning_Points_All_Lectures.txt (HLA-B5801 and HLA-B1502 screening principles in Han Chinese; pharmacogenomics)
High Yield Summary
- Paramyotonia congenita = autosomal dominant Na+ channelopathy (SCN4A, 17q23) → gain-of-function → impaired fast inactivation of Nav1.4
- Cardinal feature: Cold-induced paradoxical myotonia (worsens with repeated contraction — "warm-down") ± episodic flaccid weakness
- Pathophysiology: Persistent Na+ current → mild depolarisation = myotonia; severe depolarisation = depolarisation block = paralysis
- Triggers: Cold (primary), hyperkalaemia, exercise, rest after exercise
- Infantile onset, lifelong, non-progressive (unlike myotonic dystrophy)
- No systemic features (unlike myotonic dystrophy: cataracts, cardiac, endocrine, cognitive)
- Allelic with hyperkalemic periodic paralysis (both SCN4A) — spectrum of disease
- Key differential: Myotonia congenita (Cl⁻ channel, warm-up phenomenon), hyperK PP, thyrotoxic PP (Asian males, check TFT), hypoK PP
- Ion channelopathy framework: Minor leak → myotonia; Major leak → paralysis
- Treatment: Mexiletine (Na+ channel blocker) is first-line for myotonia; avoid cold; manage hyperkalaemia; genetic counselling
High Yield Summary
- The differential for PMC is organised around two axes: myotonia (PMC vs myotonia congenita vs DM1/2 vs SCM) and episodic weakness (PMC vs HyperK PP vs HypoK PP vs TPP vs Andersen-Tawil)
- Paradoxical myotonia (warm-down, worsens with repeated use) is essentially pathognomonic for PMC — myotonia congenita has warm-up
- Cold provocation as the dominant trigger strongly favours PMC over all other periodic paralyses
- PMC and HyperK PP are allelic (both SCN4A) with significant overlap — distinguished by whether myotonia or weakness dominates
- TPP is the most important differential in Hong Kong — always check TFT in any Asian male with episodic weakness; TPP has no myotonia, has hypoK, and has thyrotoxic features
- Myotonic dystrophy is distinguished by progressive wasting + multisystem involvement (cataracts, cardiac, endocrine, cognitive)
- Pseudomyotonia (hypothyroidism, Brody disease, neuromyotonia) can mimic the stiffness but is electrically silent on EMG
- No sensory involvement, no bulbar involvement, and no systemic features in PMC — their presence should redirect to other diagnoses
High Yield Summary
- No formal classification criteria exist for PMC — diagnosis is clinical-genetic: characteristic phenotype (cold-induced paradoxical myotonia ± episodic weakness, AD inheritance, infantile onset, no systemic features) confirmed by SCN4A genetic testing
- Essential rule-out bloods: Serum K+ (during attack if possible), TFT (rule out TPP — critical in Asian populations), CK (rule out inflammatory myopathy/dystrophy)
- EMG is the key electrophysiological test: Look for myotonic discharges (dive-bomber sound) that worsen with cooling + CMAP amplitude decrement after cooling protocol
- Pseudomyotonia (hypothyroidism, Brody disease) is electrically silent on EMG — if no myotonic discharges, it is NOT PMC
- Genetic testing of SCN4A is the gold standard — identifies pathogenic variant (T1313M, R1448C/H most common). A negative test does not exclude the diagnosis if phenotype is classic
- Muscle biopsy is rarely needed — non-diagnostic for channelopathies; reserve for diagnostic uncertainty
- ECG is done to rule out electrolyte-related arrhythmia during attacks and to exclude Andersen-Tawil syndrome and myotonic dystrophy cardiac involvement
- NCS is normal in PMC — rules out neuropathic causes of weakness
High Yield Summary
- PMC is incurable but manageable — management is symptomatic and preventive
- Cold avoidance is the single most effective intervention — many mild patients need no drugs
- Mexiletine (Class IB Na+ channel blocker) is the first-line pharmacotherapy — use-dependent block of inactivated Na+ channels reduces persistent Na+ current and myotonia. ECG monitoring required
- Second-line agents: lamotrigine, carbamazepine (HLA-B1502 screen in HK!), phenytoin, acetazolamide* (especially for weakness-dominant phenotype)
- Historical agents from lecture notes: procainamide, phenytoin, disopyramide, nifedipine, quinine sulphate [1] — mostly superseded by mexiletine in current practice
- Acute attacks: Rewarming + rest; cardiac monitoring if severe. Do NOT give K+ (unlike TPP/HypoK PP — K+ worsens PMC)
- Anaesthetic safety: Succinylcholine is CONTRAINDICATED (triggers myotonic rigidity mimicking MH). Use non-depolarising agents. Maintain normothermia. Avoid K+-containing fluids
- PMC is NOT malignant hyperthermia (SCN4A ≠ RYR1) — volatile anaesthetics are safe, but succinylcholine is not
- Genetic counselling: AD inheritance, 50% risk to offspring, high penetrance. Offer predictive testing to at-risk relatives
- Long-term monitoring: ECG + LFTs on mexiletine; muscle strength annually; QoL assessment
High Yield Summary
- PMC is a non-life-threatening but functionally significant condition — the main complications are related to functional impairment, late-onset myopathy, anaesthetic risks, and psychosocial burden
- Late-onset fixed proximal myopathy (4th-6th decade) is the most important long-term musculoskeletal complication — caused by cumulative myofibre damage from repeated depolarisation episodes and Ca²+ overload. It is irreversible
- Anaesthetic complications are the most dangerous and most preventable — succinylcholine is absolutely contraindicated (triggers myotonic rigidity mimicking MH); hypothermia must be avoided perioperatively
- PMC does NOT cause intrinsic cardiac disease (unlike myotonic dystrophy) — SCN4A (skeletal Nav1.4) ≠ SCN5A (cardiac Nav1.5). Cardiac risk is only from transient electrolyte disturbance during severe attacks
- Rhabdomyolysis is rare but can occur with prolonged severe attacks or succinylcholine exposure → monitor CK, renal function, urine myoglobin
- Treatment complications must be monitored: mexiletine → ECG (cardiac conduction); carbamazepine → HLA-B1502 screening in Hong Kong* (SJS/TEN risk); acetazolamide → renal stones, metabolic acidosis, paradoxical worsening possible
- Psychosocial impact is common and underappreciated — occupational limitation, social isolation, anxiety/depression; offer counselling and connect with support groups
- Pregnancy is not contraindicated but requires medication review (avoid carbamazepine), active warming during delivery, anaesthetist communication, and neonatal genetic counselling
Myotonia Congenita
Myotonia congenita is a hereditary skeletal muscle channelopathy caused by mutations in the voltage-gated chloride channel (CLCN1) gene, resulting in impaired muscle relaxation after voluntary contraction.
Hyperkalemic Periodic Paralysis
Hyperkalemic periodic paralysis is an autosomal dominant channelopathy caused by mutations in skeletal muscle sodium channels, resulting in episodic attacks of muscle weakness associated with elevated serum potassium levels.